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ABSTRACT 
Lei Peng: Taxane Conjugate Nanoparticles for Improved Non-small Cell Lung Cancer 
Treatment in a Novel Orthotopic Mouse Model 
(Under the direction of Russell J. Mumper) 
 
The objectives of these studies were to develop lipid-based nanoparticles (NPs) to 
deliver taxane conjugates for improved non-small cell lung cancer (NSCLC) treatment. The 
chemotherapy agents Taxol, Abraxane and Taxotere have been limited by severe side effects, 
sub-optimal pharmacokinetic profile, and moderate therapeutic efficacy. Therefore, 
Paclitaxel (PX) or Docetaxel (DX) was formulated in lipid-based NPs in these studies to 
achieve improved therapeutic index for NSCLC treatment. The NPs were engineered from 
oil-in-water microemulsion precursors with Miglyol as the oil core, and polyoxyl 20-stearyl 
ether (Brij 78) and D-alpha-tocopheryl polyethylene glycol succinate (TPGS) as the 
surfactants, and abbreviated as BTM NPs.  
A novel orthotopic NSCLC mouse model was established and characterized for in 
vivo evaluation of the developed formulation. During the effort of developing an orthotopic 
NSCLC mouse model, three different surgical procedures including intrabronchial injection, 
chest injection into left lung and dorsal injection into left lung were investigated. The 
preferred model was established through dorsal side injection of luciferase-expressing A549 
cells and then characterized by overall survival, histological staining, bioluminescence 
imaging and micro PET/CT imaging. The model produced lung tumor with a 94% success 
rate and a reliable bioluminescence signal for long-term tumor growth monitoring. The 
 therapeutic efficacy of 2’-(2-bromohexadecanoyl)-docetaxel (Br-C16-DX) NPs versus 
Taxotere® was investigated in this model. The results demonstrated longer progression-free 
survival and median survival of the NP-treated group as compared to the Taxotere group. 
 For PX delivery, a 2’-(2-bromohexadecanoyl)-paclitaxel (Br-16-PX) conjugate was 
synthesized and formulated into lipid NPs. The goals were to improve drug entrapment in the 
drug delivery system and to enhance in vivo pharmacokinetics and conversion to paclitaxel at 
the tumor site. The developed system was evaluated in luciferase-expressing A549 cells in 
vitro and in the developed orthotopic NSCLC mouse model. The results demonstrated that 
the Br-C16-PX NPs had an increased maximum tolerated dose (MTD) and an improved 
pharmacokinetic profile as compared to Taxol®, which resulted in significantly improved 
antitumor efficacy for the treatment of advanced NSCLC.  
In summary, the developed lipid-based NPs with taxane conjugate may serve as a 
safer and more efficacious treatment options for NSCLC. The developed orthotopic NSCLC 
model represents a feasible, reproducible, and clinically-relevant experimental mouse model 
to test current and potential therapies including nanomedicines.  
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CHAPTER 1. 
PACLITAXEL CONJUGATE FOR IMPROVED CANCER THERAPY 
 
1. Paclitaxel and its limitations 
Paclitaxel (PX) is a microtubule stabilization agent discovered from the bark of 
Pacific Yew (Taxus brevifolia) in the early 1960s by the U.S. National Cancer Institute. It is 
a white crystalline powder with a melting point of ~210° (Figure 1.1, C47H51NO14, MW 
853.93). PX has been widely used as a chemotherapeutic drug mainly to treat lung, ovarian 
and breast cancer [1]. It works through promoting tubulin polymerization which leads to 
formation of abnormally stable microtubules. The lack of microtubule dynamics during 
mitosis further results in cell arrest at G2-M phase and apoptotic cell death of fast-
proliferating cells.  
The use of PX has been limited by its low water solubility (~0.4 µg/ml). The first 
commercial product Taxol® was approved by the FDA in 1992, in which PX is formulated in 
organic solvents of polyoxyethylated castor oil (Cremophor EL) and dehydrated ethanol 
(50/50, v/v). However, the high amount of toxic co-solvents, especially Cremophor EL, leads 
to serious side effects including anaphylaxis and severe hypersensitivity [2]. Premedication 
with corticosteroids, diphenhydramine, and H2 antagonist is required prior to Taxol 
administration to prevent severe hypersensitivity reactions but fatal reactions still occur 
despite pretreatment. Furthermore, Taxol exhibits non-linear, thus less-predictable, 
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pharmacokinetics in vivo [3].  
Abraxane, an albumin-bound paclitaxel nanoparticle (mean diameter 130 nm), was 
approved by the FDA in 2005 for the treatment of breast cancer and later in 2012 for the 
treatment of non-small cell lung cancer (NSCLC). In the phase III trial CA-031, weekly 
albumin-bound paclitaxel (nab-PX) plus carboplatin was compared with solvent-based 
paclitaxel (sb-PX) plus carboplatin in advanced NSCLC patients [4]. Although Nab-PX 
exhibited decreased toxicity, the 10% improvement of progression-free survival (p = 0.21) 
and overall survival (p = 0.27) were not statistically significant. Moreover, although 
Abraxane exhibited linear, thus more predictable, pharmacokinetic profile, the half-life (p = 
0.48) and area under the concentration versus time curve (AUC, p = 0.52) of Abraxane at 260 
mg/m2 were not significantly increased as compared to Taxol at 175 mg/m2 [5].  
Due to the challenges in directly formulating PX, conjugates of PX have been 
investigated either to have greater water solubility thereby decreasing the amount of toxic co-
solvents, or to increase the lipophilicity and subsequently formulate into hydrophobic drug 
delivery systems. Most conjugates are synthesized through modification of the C-2’ and/or 
C-7 hydroxyl groups due to the chemical reactivity [6]. The 2’-OH is typically more reactive 
likely due to less steric hindrance than the 7-OH. Therefore, a majority of the conjugates are 
synthesized via the 2’-OH. Both hydroxyl groups are important for the cytotoxic activity of 
PX thus conjugation at these sites could lead to PX conjugates with compromised antitumor 
activity [6-8]. In this review, various PX conjugates including small molecule conjugates, 
polymeric conjugates, protein/peptide conjugates and the conjugate-loaded nanosystems will 
be discussed.  
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2. Small Molecule Conjugates 
2.1 Water-soluble small molecule conjugates 
Because the water solubility of PX is very low, early efforts of developing PX 
conjugates focused on improving its water solubility in order to minimize the use of toxic co-
solvents. Water-soluble PX conjugates including succinate, glutarate, sulfonate, amino acid, 
carbonate, phosphate, and peptide conjugates were synthesized and evaluated.  
 
2.1.1 Early Development  
Investigations of PX conjugates were initiated in late 1980s and were focused on 
improving water solubility in early development. Major conjugates are PX C-2’ and C-7 
esters such as succinate, glutarate, sulfonate and amino acid and carbonate [9-11]. Despite 
improved water solubility, the C-2’ conjugates were not stable in aqueous medium or human 
plasma, and the C-7 conjugates readily released the parent drug PX and thus did not usually 
exhibit prodrug properties, leading to reduced antitumor activity in vivo as compared to PX. 
Nicolaou et al. synthesized a series of PX 2’-monoester of dicarboxylic acid in 1993 [12]. 
This study underlines the importance of the electron-withdrawing group in the side chain, 
wherein increased release of PX was observed with the electron-withdrawing ability of the 
aryl substitutes or the linking heteroatom. These protaxols were demonstrated to have similar 
cytotoxicity to PX but only modestly improved water solubility. Later, Nicolaou et al. 
prepared PX-2’-methylpyridinium acetate (PX-2’-MPA), which was shown to be orders of 
magnitude more soluble in water than PX [13]. However, these conjugates were designed to 
release the parent drug PX under basic or physiological condition based on the hypothetical 
4 
basic tumor microenvironment. As more studies have established the relatively acidic 
conditions in tumor tissue, development of these conjugates were discontinued. One 
promising category of small molecule conjugates are PX-2’-carbonates [11]. Although 10-
fold less toxic than PX in human colon cancer cell line HCT116, the PX-2’-carbonates 
released PX in a murine lung carcinoma (M109) model and achieved longer survival than 
PX. However, due to low water solubility, the PX-2’-carbonates were administered i.p. in 
10% DMSO or 10% Tween 80.  
 
2.1.2 Phosphate esters 
Phosphate ester derivatives of PX gained the popularity due to increased water 
solubility and in vivo release of PX under phosphatase activation. Bristol-Myers Squibb 
(BMS) developed PX derivatives by attaching phosphate group at the 2’- or 7- hydroxyl 
group, respectively [14]. These conjugates exhibited improved water solubility (> 10 mg/ml) 
but remained intact in plasma and against alkaline phosphatases, leading to lack of in vivo 
efficacy. It was hypothesized that the attachment of the phosphate group was too close to the 
PX nucleus to be accessible for phosphatase cleavage. Later, BMS synthesized a “trimethyl 
lock” linker which could be released quickly via intramolecular cyclization [15]. With the 
self-immolating linker, both the C-2’ conjugate and the C-7 conjugate released the parent 
drug in vitro under phosphatase cleavage. However, the C-2’ conjugate showed low activity 
in vivo and the C-7 conjugate showed similar activity to PX only with a 2- to 4-fold greater 
dose. This was likely due to extensive binding of the conjugates to plasma proteins in vivo 
and insufficient release of PX. Further efforts combined the carbonate approach and the 
phosphate approach where the carbonate group and phosphate group was conjugated at 2’-
5 
OH and 7-OH, respectively [16, 17]. The resulting compound had 1000-fold greater water 
solubility than PX and similar antitumor efficacy in M109 murine lung carcinoma model.  
 
2.1.3 Peptide conjugates  
Synthetic peptides have the advantages of smaller size, cost-effective production and 
low immunogenicity as compared to large proteins or antibodies. Several peptide PX 
conjugates have been investigated including cell penetrating peptide [18, 19], integrin-
targeting RGD peptide [20, 21], and peptides that target HER-2 [22]. However, the majority 
of the studies reported only in vitro cytotoxicity with limited or untested in vivo efficacy.  
One promising approach was the octaarginine transporter which was attached to the 
C2’ or C7 positions of PX by a cleavable disulfide linker [18]. The C2’ conjugate (Figure 
1.2A) was shown to be more effective than the C7 conjugate and free PX in a mouse model 
with human ovarian carcinoma cell line UCI 101. Importantly, the PX-octaarginine was 
demonstrated to overcome Pgp and induce cell death in resistant cancer cells. Although the 
C7 conjugate produced similar effect as free PX in mice implanted with sensitive OVCA-429 
cells, it significantly prolonged survival relative to PX in resistant mouse model with OVCA-
429T cells.  
Another encouraging study was performed by Zhang et al., where sequential targeting 
micelles were developed to first penetrate blood brain barrier via transferrin and then deliver 
the PX-2’-c[RGDfK] conjugate (Figure 1.2B) specifically to integrin-overexpressed glioma 
cells [21].  Transferrin modification significantly enhanced cellular uptake of the micelles by 
primary brain microvascular endothelial cells, producing enhanced drug accumulation in the 
brain after intravenous injection. Furthermore, the sequential targeting micelles produced 
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longer mean survival (42.8 days) in mice bearing intracranial U-87 MG glioma as compared 
to mice treated with transferrin modified PX loaded micelle (39.5 days), PX loaded micelle 
(34.8 days) or free PX (33.6 days).  
 
2.2 Lipophilic small molecule conjugates  
Drug delivery systems including nanoparticles (NPs) have been developed to deliver 
PX and to utilize the advantages of nanosystems including EPR (enhanced permeability and 
retention) effect, prolonged circulation, and active targeting. Despite low water solubility of 
PX, its solubility in many lipids is also limited, leading to compromised drug entrapment and 
drug retention in lipid-based NPs. Therefore, more lipophilic PX conjugates were developed 
to enhance the drug entrapment and drug retention in hydrophobic drug delivery systems.   
   
2.2.1 Fatty acid conjugates  
Fatty acid has been investigated extensively to produce lipophilic PX conjugates 
through forming an ester bond with the 2’-OH group. It has been suggested that some fatty 
acids may serve as biochemical precursors or energy sources for tumors thus are taken up 
from arterial blood into tumor cells. Improved pharmacokinetic profile could be achieved 
when the conjugate is incorporated into nanosystems. Lundberg et al. prepared a lipid 
emulsion with PX-2’-oleate conjugate (Figure 1.3A) with a particle size of 50 nm [7]. The 
PX-2’-oleate was much more lipophilic than PX with decreased water solubility from 12.8 
µM to 34 nM and increased Ko/w from 311 to 8,074. Pharmacokinetic studies in rabbits 
proved significantly greater AUC, higher Cmax, lower systemic clearance and lower volume 
of distribution (Vd) for the lipid emulsion with PX-2’-oleate as compared to free PX in lipid 
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emulsion or free PX in Cremophor EL/ethanol. The delivery vehicle helped to improve the 
pharmacokinetic profile and the increased lipophilicity of the conjugate as compared to PX 
enhanced drug retention in the vehicle. Further evaluations of the in vivo efficacy showed 
moderate advantage of the liposome formulation as compared to commercial PX in B16F10 
(murine melanoma) tumor bearing mice [23].   
Benita and co-workers synthesized a PX-2’-palmitate formulated in different targeted 
systems. The PX-palmitate was incorporated in cationic immunoemulsions with anti-HER2 
monoclonal antibody (Herceptin) for the treatment of prostate cancer [24]. The drug-loaded 
immunoemulsions did not activate the complement as compared to the commercial and PX-
palmitate hydroalcoholic formulations. Furthermore, the immunoemulsion had significantly 
improved tumor growth inhibition in vivo as compared to the untargeted cationic emulsion (p 
< 0.05) and the paclitaxel palmitate hydroalcoholic formulations (p < 0.01). Later, the 
conjugate was formulated in pegylated polyester immunonanoparticles which showed 
significantly increased t1/2, Cmax and AUC values as compared to the PX-palmitate solution 
[25]. Moreover, the targeted immunonanoparticles had decreased liver and spleen 
accumulation than untargeted NPs. Recently, the same conjugate was formulated in PLGA 
NPs with an anti-EGFR antibody cetuximab [26]. Significantly greater tumor growth 
inhibition and increased survival rates were observed in a metastatic lung cancer mouse 
model as compared to the non-targeted drug solution and non-targeted drug NPs.  
The release kinetics of parent drug from PX conjugate plays a crucial role for the 
therapeutic performance of the formulation. Ansell et al. synthesized a series of lipophilic PX 
prodrugs formulated in micelles or NPs [27]. Either succinic acid or diglycolic acid was used 
as the linker between 2’-OH of PX and the fatty acid chain, with the latter found to be more 
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susceptible to hydrolysis.  In vitro studies in A2780 and MCF-7 cells showed 3 to10-fold and 
30 to 90-fold greater IC50 of the succinate-linked conjugates as compared to the diglycolic-
linked conjugates, respectively, presumably due to lack of release of active PX from the more 
stable succinate bond.  Furthermore, NPs containing succinate prodrug were ineffective in 
vivo in a xenograft mouse model with HT29 human colon carcinoma tumor, while NPs 
loaded with diglycolate prodrug were demonstrated to inhibit tumor growth. Interestingly, 
the antitumor activity of the diglycolate prodrug-loaded NPs was correlated with the aliphatic 
chain length, with the longer chain leading to improved efficacy. This was due to the longer 
partitioning half-lives of the more lipophilic conjugates from the lipid NPs which lead to 
sustained release and subsequent activation by esterase to produce PX.  
 Besides modulating fatty acid chain length and linker chemistry, different research 
groups have also investigated the inclusion of an electron-withdrawing group on the fatty 
acid chain to make the ester bond more cleavable. Mayhew and co-workers synthesized a 2’-
α-bromohexadecanoyl PX conjugate in which hydrolysis of the prodrug was accelerated by 
the electron-withdrawing bromine atom at the α position of the acyl chain [28-31]. The 
bromohexadecanoyl prodrug was first administered dissolved in Cremophor EL and it 
showed improved in vivo activity as compared to PX in a subcutaneous human ovarian 
cancer (OVCAR-3) mouse model.  Later, Mayhew and co-workers incorporated the prodrug 
in a liposomal formulation to avoid the use of Cremophor. Liposomes with 2’-α-
bromohexadecanoyl PX were demonstrated to have superior antitumor efficacy in vivo as 
compared to PX.  
Docosahexaenoic acid-PX (DHA-PX, Figure 1.3B) is the most successful PX-fatty 
acid prodrug in which the 22-carbon DHA was linked to PX via an ester bond at 2’-OH [32-
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38]. DHA is a natural fatty acid found in human milk and is classified as a nutritional 
additive by the FDA. The DHA-PX is a prodrug without microtubule stabilization activity. It 
must be converted to active PX to be effective. It was demonstrated that the AUCs of PX 
from DHA-PX were 1.7- and 5.8-fold greater than those of PX at equimolar and equitoxic 
doses in an M109 mouse tumor model. A complete tumor regression was observed at 120 
mg/kg of DHA-PX, while no significant tumor suppression was observed for equitoxic PX at 
20 mg/kg [32]. Furthermore, DHA-PX was a 4-fold weaker substrate for Pgp as compared to 
free PX and therefore may be effective in treating resistant tumors. DHA-PX has been 
investigated in clinical trials for the treatment of melanoma and decreased toxicity compared 
to conventional therapy was observed (no hypersensitivity, no hair loss, and mild nausea) 
[35-38]. Weekly administration appeared to be a better dosing regimen as compared to a 
single dose administered every three weeks for the treatment of solid tumors. However, it 
should be noted that although DHA-PX was formulated in 80% less Cremophor EL than 
Taxol, both Cremophor EL and ethanol were still present in the DHA-PX formulation.  
 
2.2.2 Other lipophilic small molecule conjugates 
Stevens et al. synthesized a PX-2’-carbonyl-cholesterol (Figure 1.4A) with increased 
lipophilicity and incorporated it into folate-targeted lipid NPs of 130 nm size [39]. The 
formulation had a drug incorporation efficiency of greater than 90% and exhibited antitumor 
activity both in vitro and in vivo. Furthermore, the targeted NPs significantly prolonged 
survival in mice bearing subcutaneous M109 lung carcinoma as compared to untargeted NPs 
and free PX, indicating the importance of the targeting ligand in this formulation. Zakharian 
et al. synthesized a PX-fullerene (C60) conjugate (Figure 1.4B) with a succinate linker which 
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was shown to release PX in bovine plasma with a half-life of 80 min [40]. The conjugate was 
then incorporated into a liposomal formulation with a size of 2.77 µm for aerosol delivery to 
treat lung cancer. Moderate cytotoxicity was observed in A549 cells and in vivo evaluation 
of the system was not performed.  
 
3.    Polymeric Conjugates 
Linear polymers including poly(ethylene glycol), hyaluronic acid, N-(2-
hydroxypropyl)-methacrylamide and Poly(L-glutamic acid) have been investigated to 
conjugate PX for improved hydrophilicity and/or to be incorporated in NPs.  
 
3.1   Poly(ethylene glycol) 
Poly(ethylene glycol) (PEG) is one of the most popular conjugation polymers in 
prodrug approach due to its high water solubility and biocompatible nature. PEG goes 
through renal or hepatic elimination in the body and has been approved for human use.  
 
3.1.1 PX-PEG conjugates as injectable solutions 
The first series of PX-PEG conjugates (Figure 1.5A) was synthesized by Greenwald 
et al. in the 1990s, in which PEG polymer was conjugated with PX at the 2’-OH or 7-OH 
group [41]. The 7-PEG ester had T1/2(hydrolysis) > 400 hr in PBS buffer (pH 7.4) and was 
not considered to be a practical prodrug for further development. For 2’-OH esters, PEG 
polymers of different molecular weight including 5 kDa, 20 kDa and 40 kDa exhibited 
increased water solubility for shorter PEG chain at 660 mg/ml, 200 mg/ml, and 126 mg/ml, 
11 
respectively. The conjugates of Greenwald et al. were designed to have an electron-
withdrawing group in the α-position for effective hydrolysis [12, 13]. Although all three 
conjugates had similar in vitro cytotoxicity to P388/O and L1210/O murine leukemia cell 
line as PX, the PEG chain length proved to be critical for in vivo efficacy. The 40 kDa PX-
2’-PEG conjugate showed slightly improved antitumor efficacy in a P388 mouse model 
while the 5 kDa conjugate showed lower efficacy than PX. The longer PEG chain was 
believed to be important for prolonged circulation time. Similar observations were made by 
Li et al., where a 5 kDa EPG was conjugated to the 2' position of PX through a succinyl 
group spacer [42]. This PX-2’-PEG was dissolved in saline for the treatment of solid breast 
tumor MCA-4 in vivo. However, at the same dose of 40 mg/kg, PX-treated mice showed 
slightly longer survival than the conjugate-treated group. Furthermore, mice treated with PX-
2’-PEG had a 12% weight loss compared to PX at only 5%, indicating some toxicity of the 
conjugate formulation. These results demonstrated that the molecular weight of the polymer 
utilized in the conjugation was crucial for prolonged circulation in vivo which further 
enabled therapeutic efficacy. It was then being recognized that longer circulation and 
subsequent increased accumulation in leaky tumor vasculature is an important advantage of 
nano-therapeutics including drug-polymer conjugates, which is the so-called EPR (enhanced 
permeability and retention) effect [43].   
Further efforts with PX-PEG conjugates emphasized the linker chemistry for efficient 
release of PX. Feng et al. synthesized PX-2’-PEG prodrugs with amino acid linkers and 
reported reduced side effects and comparable in vivo antitumor efficacy to PX [44]. 
Rodrigues et al. prepared maleimide derivative of PX with an acid-sensitive carboxylic 
hydraxone linker, which was expected to enable PX release in the slightly acidic tumor 
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microenvironment or in the endosomes or lysosomes of tumor cells after endocytosis [45, 
46]. However, only cytotoxicity data was reported and in vivo efficacy remains to be 
evaluated. Zhang et al. performed similar studies with a PX-PLA-PEG block copolymer 
conjugate and demonstrated antitumor activity in vitro against H7402 human liver cancer 
cells [47].  
 
3.1.2 PX-PEG conjugates for oral delivery 
PX-PEG conjugates have also been investigated for improved oral bioavailability. PX 
has low oral bioavailability due to low water solubility and drug efflux by Pgp transporter 
which is abundant in the gastrointestinal tract. Choi et al. demonstrated improved 
bioavailability of a PX-7-PEG conjugate after oral administration in rat [48-50]. 
 
3.1.3 PX-PEG conjugates formulated in nanosystems 
To utilize advantages of nanosystems including EPR effect, prolonged circulation and 
potential active targeting, PEG-PX conjugates have been incorporated into liposomes [51] 
micelles [52-54], or nanoparticles [55-58]. Ceruti et al. synthesized 2’-succinyl, 2’-
methylpyridinium acetate and 2’-mPEG ester PX derivatives to enhance drug entrapment 
efficiency in their liposome formulation [51]. Liposomes containing 2’-mPEG (5000)–PX 
showed the best stability, entrapment efficiency and drug concentration compared to 
liposomes with 29-succinyl, 29-methylpyridinium acetate. Furthermore, the terminal half-life 
of liposomes with 2’-mPEG-PX (47.16 hr) was significantly prolonged compared to free PX 
(1.31 hr), indicating the prolonged circulation provided by the delivery vehicle.  
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Alani et al. synthesized PEG-PX conjugates with different amino acid linkers which 
assemble into unimodal polymeric micelles with diameters of 42 nm or 137 nm [52]. These 
micelles exhibited comparable cytotoxicity against SK-OV-3 and MCF-7 cancer cell lines as 
compared to PX but the in vivo efficacy remains uncertain. Forrest et al. reported similar 
findings [53]. Targeting ligand has been investigated to increase tumor cell uptake. Wan et 
al. prepared folate-targeted micelles from PX conjugate copolymers and evaluated the in vivo 
performance in Lewis lung cancer mouse model [54].  
Linkers sensitive to tumor microenvironment were developed for tumor-specific 
release of PX from the conjugate. Ding et al. delivered thiol-terminated PX-PEG conjugate 
on the surface of gold nanoparticles [55]. The system was designed for synergic drug release 
behavior in the presence of both esterase and high concentrations of glutathione and was 
proven to have superior in vivo efficacy compared to free drug. Cathepsin B-sensitive or 
MMP2-sensitive PX-PEG conjugates have also been developed and were shown to have 
improved efficacy in mouse models [56, 57].  
 
3.1.4 Dendritic PX-PEG conjugates 
One limitation of PEG conjugates is the limited reaction sites due to the linear 
structure and functional groups only at the two ends. To increase the drug and ligand 
payload, Clementi et al. synthesized a dendrimer structure at one polymer end chains to 
attach multiple targeting ligands based on the considerations that the selective cytotoxicity of 
the conjugates increased with the number of targeting molecules per polymer chain [59, 60]. 
This heterobifunctional PEG had one PX molecule at one end and four bone-targeting 
alendronate molecules on the other (Figure 1.5B). Furthermore, the PX-PEG-(alendronate)4 
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conjugates self-assembled into ~ 200 nm NPs which enabled utilization of the EPR effect. 
This formulation exhibited similar cytotoxicity to free drug and improved pharmacokinetic 
profile. However, the in vivo efficacy against cancer bone metastases remains to be evaluated 
[59].  
 
3.2. Hyaluronic acid 
Hyaluronic acid (HA) is a biocompatible and biodegradable linear polysaccharide 
containing two alternating units of D-glucuronic acid and N-acetyl-D-glucosamine. It targets 
over-expressed HA receptors in malignant tumors such as CD44 and hyaluronan-mediated 
motility receptor (RHAMM) [61]. Moreover, HA allows multiconjugation of the delivered 
molecule via free carboxylic groups that are available in each repeating unit leading to 
increased drug loading. Taken together, the biocompatibility, multivalency and tumor-
targeting effect make HA a promising polymer for tumor-targeted drug conjugation [62].  
 Luo et al. synthesized a 11 kDa HA-PX ester conjugate with a drug loading of 1-15% 
(Figure 1.6) and showed effective cytotoxicity against a series of cell lines with 
overexpressed HA receptors via receptor-mediated endocytosis [63, 64]. It was demonstrated 
that increased cytotoxicity was associated with higher drug loading of PX. However, when 
drug loading was increased to 15%, the cytotoxicity of the conjugate decreased likely due to 
blockage of HA receptor binding site by the PX moieties. Similarly, Galer et al. synthesized a 
HA-PX conjugate with 7% PX loading for the treatment of squamous cell carcinoma of the 
head and neck with CD44 overexpression [65]. The resulting conjugate showed comparable 
cytotoxicity in OSC-19 and HN5 cell lines to PX as well as superior therapeutic efficacy in 
an orthotopic mouse model.  
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 Nanosystems have been developed with HA-PX conjugates. Xin et al. synthesized 
HA-PX conjugates with amino acid linkers which self-assemble into spherical NPs around 
280 nm [66]. These HA-amino acid-PX conjugates exhibited enhanced cytotoxicity in breast 
cancer cell lines and the in vivo activities remain to be evaluated. Lee et al. developed HA-
paclitaxel conjugate NPs around 196 nm by conjugating PX to the nanocomplex of HA and 
PEG, and increased uptake of the NPs was observed in HA receptor overexpressing cancer 
cells compared to HA receptor deficient cells [67].  
  Chitosan has been utilized to form polyelectrolyte complex NPs or self-assembled 
polyelectrolyte multilayers with HA-PX conjugate. Li et al. prepared chitosan/hyaluronic 
acid-paclitaxel complex NPs with 10.6 wt % of PX for oral delivery [68]. In vitro release of 
the chitosan/HA-PX was evaluated with a pH range from 3.0 to 7.4 simulating the pH 
environments in the fasting stomach (pH ~ 3.0), intestine (pH ~ 6.0) and the body fluid at 
intercellular spaces (pH ~ 7.4). A pH-sensitive release of PX was observed with increased 
release at a higher pH. Thierry et al. constructed polyelectrolyte multilayers with HA-PX and 
chitosan by the layer-by-layer technique [69]. This drug delivery platform is potentially 
applicable to colloids, biomedical implants, or vascular tissues. However, one limitation was 
that the drug loading of PX in HA-PX conjugate was only 3 mol % in order to preserve 
sufficient water solubility in aqueous NaCl solutions for fabrication by the standard layer-by-
layer technique. 
 
3.3 N-(2-hydroxypropyl)-methacrylamide (HPMA) 
The N-(2-hydroxypropyl)-methacrylamide (HPMA) copolymer has been investigated 
for drug delivery due to its biocompatibility and water solubility. PX was covalently linked 
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to HPMA at the 2’-OH (Figure 1.7) with a polymer/drug ratio of 19/1 (w/w). The Gly-Phe-
Leu-Gly linker utilized in this conjugate (PNU 166945) went through enzymatic cleavage 
under the activity of thio-dependent lysosomal proteases to release the parent drug PX [70, 
71]. PNU 166945 was the first polymer-PX conjugate tested in Phase I clinical trial and was 
administered as a 1 hr infusion every three weeks at a starting dose of 80 mg/m2 [72]. Despite 
some antitumor activity, the trial was discontinued due to neurotoxicity. Grade 2 
neurotoxicity was observed in two out of twelve patients at a dose of 140 mg/m2 and grade 3 
neuropathy was observed in one patient at 196 mg/m2.  
 
3.4 Poly(L-glutamic acid)  
The most promising polymeric conjugate to date has been PX poliglumex (Xyotax 
or CT-2103, Figure 1.8A).  It has been extensively investigated in clinical trials for the 
treatment of multiple cancer types [73-87].  Poly(L-glutamic acid) was conjugated to the 2’-
OH of PX via an ester linkage susceptible to lysosomal protease cleavage, especially 
cathepsin B [88, 89]. There were several phase III trials where CT-2103 was being used as a 
single agent or in combination with others for the treatment of non-small cell lung cancer 
[76, 90-93].  Overall survival was similar for CT2103/carboplatin versus PX/carboplatin, 
single-agent CT-2103 versus single-agent gemcitabine or vinorelbine, and single agent CT-
2103 versus single agent docetaxel. Although no significant difference was observed, a 
strong trend for a survival advantage in favor of CT-2103 was noted in women compared to 
men. Therefore, a phase III clinical trial with only female patients was carried out and the 
results have not been published yet [90]. Noteworthy, the systemic toxicity associated with 
CT2103 in clinical trials was significantly decreased compared to conventional therapies. 
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Most recently, the combination of CT-2103 with temozolomide and concurrent radiation was 
investigated for high-grade glioma  treatment [94]. It turns out that the combination of CT-
2103 with temozolomide lead to grade 4 neutropenia, thrombocytopenia, and/or anemia in 6 
out of 25 patients. The hematological toxicity was likely caused by the drug-drug interaction 
between CT-2103 and temozolomide. A randomized study to compare CT-2103/radiation 
versus temozolomide/radiation for glioblastoma is planned. 
Since CT-2103 has not been shown to have significant survival improvement in phase 
III trials, and CT-2103 has not been reported to self-assemble into nanoparticles, Van et al. 
prepared nanoconjugates of poly(L-γ-glutamyl-glutamine)-PX (PGG-PX, Figure 1.8B) 
aiming to further enhance the therapeutic efficacy [95]. The PGG-PX self-assembles into 12–
15 nm NPs, and exhibited comparable cytotoxicity as CT-2103 against human lung cancer 
cell H460. However, the in vivo efficacy of PGG-PX has not been fully evaluated.  
 
4. Dendrimer 
Dendrimer-PX conjugates have been developed with the advantages of multiple end 
groups and potential EPR effect given sufficient size. Scheeren et al. reported a PX-
dendrimer conjugate (Figure 1.9) which was designed to release four paclitaxel leaving 
groups all together upon a single triggering event in the dendritic core [96]. Under mild 
reducing condition with Zn and AcOH, a chain reaction was initiated to release the parent 
drug PX from this “cascade-release dendrimer”.  This mechanism is advantageous for 
targeted activation at the tumor tissue considering that one single action of a tumor-specific 
factor would trigger the release of multiple drug molecules.  
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The polymeric structure has been shown to have an impact on the anticancer effect of 
PX. Khandare et al. compared a polyamidoamine (PAMAM) G4 hydroxyl-terminated 
dendrimer with a conventional linear PEG polymer in terms of PX conjugation and cytotoxic 
activity [97]. PX was conjugated to the PAMAM dendrimer at 2’-OH group via a succinate 
linker (Figure 1.10). Both the dendrimer and the bis(2-carboxyethyl)-PEG-PX increased 
water solubility of the compound and enhanced cell penetration as observed in A2780 human 
ovarian carcinoma cells. However, the release of PX from the conjugates under the presence 
of esterase at pH 7.4 occurred more slowly with the dendrimer conjugate. About 30% of PX 
was released from PEG-PX at 24 hr while 30% release from the PAMAM-PX was achieved 
after 48 hr likely due to steric hindrance to the enzyme caused by the bulky dendrimer 
structure. Moreover, the IC50 of the dendrimer conjugate (1.03 ± 0.06 ng/ml) against A2780 
was shown to be significantly lower than free PX (11.3 ± 0.3 ng/ml) while the IC50 of the 
PEG-PX (291 ± 22 ng/ml) to be significantly greater.  
 Lim et al. synthesized a triazine dendrimer derivatized with PX and PEG chain in 
which PX was conjugated at the 2’-OH via an ester bond [98, 99]. To increase the activity of 
a first generation prodrug that contained twelve paclitaxel molecules tethered via an ester 
linkage, the second generation prodrug was prepared with linkers containing both an ester 
and a disulfide (Figure 1.11). The second generation dendrimer had 8-9 PEG chains and 12 
PX per dendrimer with a 28 wt % drug, and was shown to have comparable tumor inhibition 
activity as Taxol and Abraxane in mice bearing PC3-h-luc xenografts. However, to date, the 
in vivo benefit of the labile disulfide remains unknown.  
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5. Protein conjugates of PX 
Proteins including antibodies and plasma proteins have been conjugated to PX to 
increase water solubility and to achieve targeted delivery to tumor-specific antigens or 
receptors.  
 
5.1 Antibody conjugates 
Monoclonal antibodies (mAb) have been conjugated to PX as targeting vehicles to 
selectively deliver the drug to tumor cells. The first synthesis of PX-antibody conjugates was 
reported by Guillemard et al. in 2001, where PX-2’-mAb MC192 and PX-2’-mAb 5C3 with a 
labile glutaryl group were developed for the treatment of neuroectoderm-derived tumors 
[100]. MC192 and 5C3 binds to the p75 low-affinity nerve growth factor receptor and p140 
TrkA tyrosine kinase high-affinity receptor, respectively [101, 102]. These receptors are 
normally expressed on neurons for binding with nerve growth factor, and are overexpressed 
at increased levels in multiple cancer types including small cell lung carcinoma, B-cell 
lymphoma, and melanoma [103]. The conjugates showed improved and selective in vitro 
cytotoxic activity than free PX or free PX plus free mAb. However, the in vivo antitumor 
activity of PX-MC192 was moderate, although better than free PX at equivalent 
concentrations. Correa et al. conjugated PX with an internalizing antibody BCM43/2E5 
which recognizes a mucoprotein on ovarian-cancer cells [104]. However, the PX-
BCM43/2E5 did not show significant advantage over free PX. Liu et al. developed PX 
conjugate with anti-HER2 mAb (sc7301) and the in vivo activity remains unclear [105]. 
 Monoclonal antibody against epidermal growth factor receptor (EGFR) has also been 
conjugated to PX for targeted delivery. EGFR is known to be overexpressed in breast cancer, 
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bladder cancer, ovarian cancer, non-small cell lung cancer, head and neck cancer, 
glioblastoma and meningioma [106].  Anti-EGFR mAb C225 itself has been used as an 
antitumor agent in combination with radiation [107].  Safavy et al. synthesized a PX-2’-C225 
conjugate with a succinic acid linker which was shown to have improved cytotoxicity 
compared to free PX [108]. However, the in vivo antitumor activity of the conjugate was not 
significantly better than C225 alone in nude mice bearing subcutaneous A431 tumor. The 
lack of improvement may be due to either a relatively low dose of the antibody-delivered 
drug (346 µg/kg), or suboptimal release of PX, or both.  
 The linker between PX and the mAb plays an important role for the release kinetics 
thus the in vivo therapeutic outcome. Safavy et al. compared the release profile of PX-C225 
conjugates with either a succinate linker or a more stable glutaric acid linker in a mouse 
model with DU-145 human prostate tumor [109]. It was shown that the time needed for PX 
release from the succinate-linked conjugate was shorter than the time needed for C225 tumor 
localization, while the glutarate-linked conjugate was released significantly more slowly, and 
had superior therapeutic efficacy in vivo than a physical mixture of free PX  and C225.   
The limited success in the development of antibody-PX conjugates could be due to 
suboptimal release kinetics of PX as well as the insufficient inherent cytotoxicity of PX 
itself. Only a limited number of drug molecules could be loaded on each mAb in order not to 
diminish its binding affinity to the targeted receptor. Therefore, the cytotoxic agents used in 
antibody-drug conjugates needs to be exceedingly active with an IC50 in the 10-100 pM range 
while PX was at least 10-fold less active [62]. Indeed, Ojima et al. reported a series of 
immunoconjugates of anti-EGFR mAb with highly potent second generation taxoids and 
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demonstrated significant tumor growth inhibition in an A431 xenograft mouse model [110]. 
These taxoids are not PX conjugates and are beyond the scope of discussion.  
 
5.2 Plasma protein conjugates 
Plasma proteins such as transferrin or albumin have been investigated for PX delivery 
due to their accumulation in tumor tissues as well as up-regulated receptor expression in 
tumor cells [111-113]. Transferrin is an 80 kDa glycoprotein that tightly and reversibly binds 
to Fe (III) and has been conjugated to PX for targeted delivery. Back in 1998, Bicamumpaka 
et al. synthesized PX-2’-transferrin and showed slightly decreased cytotoxicity in small cell 
carcinoma H69 as compared to PX [114]. Albumin-PX conjugates have also been evaluated 
with limited success [115-117]. Dosio et al. developed albumin-PX conjugates which showed 
moderately enhanced AUC and half-life [115]. Further conjugation of the albumin-PX with 
PEG was shown to slightly prolong half-life and decrease liver and spleen uptake, but in vivo 
efficacy is still uncertain [116].   
 
6. Summary 
In this review, various PX conjugates including small molecule conjugates, polymeric 
conjugates, dendrimer conjugates, protein conjugates, and associated nanosystems were 
discussed (Figure 1.12). A majority of these derivatives were synthesized via the most 
reactive 2’-OH group of PX, producing prodrugs with decreased or minimal antitumor 
activity until the release of the parent drug.  
PX conjugate strategies are promising for cancer chemotherapy due to several reasons 
(Table 1.1). Compared to the commercial product Taxol, the use of toxic co-solvents 
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Cremophor EL and ethanol is eliminated with PX conjugates, leading to increased maximum 
tolerated dose and decreased side effects. Moreover, tumor-specific factors such as lower pH 
or up-regulated enzymes allow for targeted activation of the prodrug, which further 
diminishes systemic toxicity to healthy tissues. Macromolecular conjugates of sufficient size 
or the incorporation of PX conjugates in nanosystems enabled EPR effect and prolonged 
circulation, leading to enhanced drug exposure to tumor cells thus improved therapeutic 
efficacy. Importantly, PX is known to be a Pgp substrate and many patients develop multi-
drug resistance after clinical treatment. PX conjugates could potentially bypass drug efflux 
transporter and raise hope for the treatment of PX-resistant tumors.  
PX conjugate strategies need to be carefully modulated and evaluated to achieve 
desirable therapeutic index. Ideally, the loaded cytotoxic agent should be released at the 
maximum tumor uptake of the conjugate or drug delivery vehicle. Premature release of PX in 
systemic circulation or deposition of only the inactive prodrug will both compromise the 
antitumor activity. The release kinetics of PX from the conjugates could be adjusted through 
manipulating linker chemistry or the conjugated moiety in terms of lipophilicity, hydrolysis-
assisting heteromolecule, and steric hindrance. Furthermore, it should be noted that 
evaluation of esterase-activated prodrugs needs to be carefully interpreted in terms of species 
difference. It was reported that PX-2’-ethylcarbonate was hydrolyzed by mouse or rat serum 
carboxylesterase but remained mostly unconverted in human serum due to the lower esterase 
expression levels in human as compared to rodent serum [11, 16, 17, 118]. There are a few 
prodrugs currently in clinical trials including CT-2103 and DHA-PX, and more remain to be 
tested in animal model or in human. 
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Figure 1.1 Structure of PX 
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Figure 1.2 PX-peptide conjugates. (A) PX-2’-octaarginine (B) PX-2’-c[RGDfK] 
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Figure 1.3 PX-fatty acid conjugates. (A) PX-2’-oleate (B) PX-2’-DHA 
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Figure 1.4 PX-lipid conjugates. (A) PX-2’-carbonyl-cholesterol (B) PX-2’-fullerene [40] 
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Figure 1.5 PX-PEG conjugates. (A) PX-2’-PEG (B) dendritic PX-PEG-(alendronate)4 [41] 
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Figure 1.6 PX-2’-hyaluronic acid 
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Figure 1.7 PX-2’-HPMA 
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Figure 1.8 (A) PX-2’-poliglumex
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 (B) PX-2’-poly(L-γ-glutamyl-glutamine) (PGG-PX)  
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Figure 1.9 PX-dendrimer conjugate showing the cascade release of PX [96] 
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Figure 1.10 PX-2’-PAMAM conjugate [97] 
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Figure 1.11 Generation 1 (left) and Generation 2 (right) PX-2’-triazine dendrimer with either 
an ester linkage or both an ester and a disulfide, respectively [98, 99]. 
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Figure 1.12 Different types of PX conjugates 
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Table 1.1 Advantages and limitations of PX and PX conjugates 
Drug Advantages Limitations 
PX 
 
Effective chemotherapy agent for 
multiple types of cancer.  
 
Strong microtubule stabilization 
activity and cytotoxicity. 
 
No conversion or activation 
needed to be effective.  
 
Very low water solubility requiring 
toxic co-solvents for administration. 
 
Limited lipophilicity leading to 
relatively low drug entrapment and 
drug retention in lipophilic drug 
delivery system.  
 
Pgp substrate. 
 
PX 
conjugates 
 
Increased water solubility or 
lipophilicity. Decreased amount or 
complete omission of toxic co-
solvents in the formulation.  
 
Enzyme- or pH- responsive 
conjugation enables tumor-specific 
activation.  
 
Macromolecular PX conjugates or 
conjugates formulated in nano-size 
drug delivery systems allow for 
EPR effect for passive targeting to 
the tumor tissue as well as 
prolonged circulation time for 
increased drug exposure.  
 
Surface modifications (pegylation, 
targeting ligand) of NPs further 
improve pharmacokinetic profile 
and tumor cell uptake of the 
formulated PX conjugate.  
 
The conjugate itself or when 
incorporated in the drug delivery 
system could potentially bypass 
Pgp to treat resistant tumors. 
 
 
Compromised tubulin polymerization 
activity and cytotoxicity due to the 
conjugation at 2'-OH or 7-OH. Release 
of the parent drug PX is needed for 
higher antitumor activity.  
 
Release kinetics of PX need to be 
modulated to achieve improved 
therapeutic index.  
 
Release kinetics could be adjusted 
through changing the conjugated 
moiety in terms of lipophilicity, 
hydrolysis-assisting heteromolecule, 
and steric hindrance, or manipulating 
linker chemistry. 
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CHAPTER 2. 
DEVELOPMENT OF A NOVEL ORTHOTOPIC NON-SMALL CELL LUNG 
CANCER MODEL AND THERAPEUTIC BENEFIT OF 2’-(2-
BROMOHEXADECANOYL)-DOCETAXEL CONJUGATE NANOPARTICLES 
 
1.    Summary 
The aims of these studies were to establish an orthotopic non-small cell lung cancer 
(NSCLC) mouse model, and to investigate the therapeutic efficacy of lipid-based 
nanoparticles (NPs) containing 2’-(2-bromohexadecanoyl)-docetaxel (Br-C16-DX) in this 
new model. A novel orthotopic NSCLC model was established in nude mice through dorsal 
side injection of luciferase-expressing A549 cells. The model was characterized by survival 
study, histological staining, bioluminescence imaging and PET/CT imaging. The therapeutic 
efficacy of the Br-C16-DX NPs versus Taxotere® was investigated in this model. The results 
demonstrated that mouse survival time was significantly prolonged by weekly intravenous 
administration of the NPs or Taxotere. Furthermore, the NPs group had 35 days longer 
progression-free survival and 27 days longer median survival as compared to the Taxotere 
group. It was concluded that the developed orthotopic NSCLC model represents a feasible, 
reproducible, and clinically-relevant experimental mouse model to test current and potential 
therapies including nanomedicines.   
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2. Introduction 
Lung cancer is the second most common cancer type and the leading cause of cancer 
mortality worldwide. The estimated death caused by lung cancer in 2012 is 29% for males 
and 26% for females in United States [119]. Lung cancer is classified into small cell lung 
cancer and non-small cell lung cancer (NSCLC) according to histological type. NSCLC 
including squamous cell carcinoma, adenocarcinoma, and large cell carcinoma accounts for 
84% of all lung cancer cases.  
The average five-year survival of NSCLC is only 15% with current therapies [119]. 
Safer and more effective treatment options are in great demand. A major hurdle of lung 
cancer research for novel therapeutics has been lack of an easily feasible, reproducible, and 
clinically-relevant experimental mouse model. Orthotopic models have the advantage over 
ectopic models in that tumor grows in a microenvironment similar to clinical condition. Lack 
of metastasis and altered drug responses have been reported in commonly used subcutaneous 
tumors, which makes orthotopic models more favorable [120, 121]. Reported methods to 
establish orthotopic lung cancer mouse models with cell injection include injection through 
the trachea or chest wall [122-125]. However, a majority of the studies are still performed in 
subcutaneous models due to lack of feasibility and reproducibility of previously reported 
models [126]. In this paper, we report our findings wherein we established and characterized 
a bioluminescent orthotopic NSCLC model which provides high lung tumor development 
rate, low surgery mortality, good heart protection, and reliable bioluminescence signal for 
long term tumor growth monitoring.  
Among the standard of care for NSCLC, docetaxel (DX) has been utilized either in 
combination with platinum-based drug or as a single agent [127]. Similar to other lipophilic 
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chemotherapy agents, its use has been limited by low water solubility, severe side-effects, 
and drug resistance. Side effects of DX such as anemia, allergy and low white blood cell 
count are partially caused by polysorbate 80 and ethanol in its commercialized form Taxotere 
(Sanofi-Aventis, Bridgewater NJ). Nanosystems including liposomes, micelles and 
nanoparticles have been investigated as safer formulations for DX delivery, where the use of 
polysorbate 80 and ethanol is avoided. Nanosystems provide advantages of decreased 
toxicity, prolonged circulating time, EPR effect and potential targeted delivery [128-131]. 
However, most DX formulations still face one or both major limitations of moderate drug 
solubility and rapid drug release in vivo.  
Previously, our group investigated the possibility to deliver DX with our lipid-based 
BTM NPs (abbreviation from NP components Brij 78, Vitamin E TPGS and Miglyol 808). 
Although DX has low water solubility, its solubility and affinity to the Miglyol oil core of 
BTM NPs was not high enough, leading to relatively low drug entrapment of DX and rapid 
drug release in vivo. To increase lipophilicity and subsequently drug entrapment and drug 
retention, a series of lipid-ester conjugates of DX with different fatty-acid chain lengths (12, 
18, and 22) were successfully synthesized and incorporated into BTM NPs with significantly 
greater entrapment efficiencies (50-60%) [132]. However, a common problem with taxane 
derivatives is the compromised cytotoxicity due to sub-optimal hydrolysis kinetics of these 
conjugates to release the parent drug. To overcome this limitation, a novel 2-Br-C16-DX 
conjugate was synthesized in more recent studies, where the presence of a bromine (Br) at 
the 2-position of the fatty acid chain leads to faster hydrolysis kinetics to release DX [30]. 
Therapeutic efficacy of this system was investigated in the developed orthotopic NSCLC 
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model. The Br-C16-DX NPs had superior therapeutic efficacy over Taxotere, as evidenced 
by the delayed tumor-relapse and prolonged overall survival.   
 
3. Materials and Methods 
Materials 
D-luciferin potassium salt, Caliper IVIS Lumina II and Living Image software were 
from Caliper (Hopkinton, Massachusetts). RPMI 1640, DPBS were purchased from 
Invitrogen (Carlsbad, California). Matrigel was purchased from BD Biosciences (San Jose, 
California). Primary antibodies for multidrug resistance-associated protein 1 (MRP1), lung 
resistance-related protein (LRP) and p-glycoprotein (Pgp) were purchased from BIOSS 
(Woburn, Massachusetts). Primary antibody for glutathione S-transferase π (GST-π) was 
purchased from Millipore (Billerica, Massachusetts). Polyoxyl 20-stearyl ether (Brij 78) was 
purchased from Uniqema (Wilmington, Delaware). D-alpha-tocopheryl polyethylene glycol-
1000 succinate (Vitamin E-TPGS) was purchased from Eastman Chemicals (Kingsport, 
Tennessee). Miglyol 808 was purchased from Sasol (Witten, Germany). Docetaxel Injection 
Concentrate was purchased from Winthrop (Bridgewater, New Jersey).  
 
Cell Culture  
Luciferase expressing human lung adenocarcinoma cell line A549-luc-c8 (Caliper, 
Hopkinton, Massachusetts) was maintained in RPMI 1640 supplemented with 10% FBS. 
Cells were cultured in a humid incubator with 5% CO2 at 37 °C.  
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In vitro bioluminescence imaging of A549-luc-c8 cells 
Serial dilutions of A549-luc-c8 cells were prepared in 12-well plates with triplicates 
per cell number at 104, 521, 1562, 3125, 6250, 25000, 50000, 200000 cells/well. D-luciferin-
potassium salt (Caliper, Hopkinton, MA) reconstituted in DPBS was added to each well to 
reach final concentration 150 µg/ml. Plates were imaged by Caliper IVIS Lumina II. Average 
radiance (p/s/cm2/sr) of each well was quantified by Living Image (Caliper, Hopkinton, MA). 
 
Lung tumor implantation through chest wall 
After mice were anesthetized with ketamine, domitor, and lidocaine hydrochloride, a 
5 mm incision was made on the chest wall over left lung, fat and muscles were separated to 
visualize the lung. A549-luc-c8 cells suspended in PBS/matrigel were injected directly into 
the left lung parenchyma. The wound was closed with a surgery clip. Mice were imaged with 
the Caliper IVIS Lumina II after tumor implantation. Hearts and lungs were taken out and 
imaged separately, and as compared to that with dorsal side tumor implantation. 
 
Dorsal side orthotopic lung tumor implantation and survival study  
Four to six week old female nude mice (Harlan Sprague Dawley) were housed in a 
pathogen-free room. Mice were anesthetized with 100 mg/kg ketamine i.p., 1 mg/kg domitor 
i.p., and topical 0.33% lidocaine hydrochloride. A 5 mm incision was made on dorsal side 
over left lung, about 1.5 cm above the lower rib line. Fat and muscles were separated to 
visualize lung movement. Luciferase expressing A549-luc-c8 cells suspended in 30 to 40 µl 
PBS/matrigel were injected directly into left lung parenchyma at the depth of 3 mm. The 
wound was closed with a surgery clip, which was removed 7 days later. After tumor cell 
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injection, 2.5 mg/kg Antisedan was administered subcutaneously for the reversal from 
sedation. Mice were placed on a heating pad during and after the surgery procedure until they 
recover from anesthesia. One million A549-luc-c8 cells were injected per mouse during 
initial method development. However, in survival studies (n = 34), five million A549-luc-c8 
cells were injected per mouse to achieve desirable survival time. All mouse studies were 
conducted according to a protocol approved by the University of North Carolina Institutional 
Animal Care and Use Committee. Mice were sacrificed when Body Condition Scoring was 2 
or less, or at 20% weight loss [133].  
 
Whole-body bioluminescence imaging  
Weekly whole-body bioluminescence imaging was performed in mouse studies to 
monitor orthotopic lung tumor growth. D-luciferin potassium salt reconstituted in DPBS was 
injected intraperitoneally at 150 mg/kg. Mice were anesthetized with 2% isoflurane and 
imaged by Caliper IVIS Lumina II fifteen minutes after luciferin injection. The Region of 
Interest (ROI) was defined as 3.2 cm radius circle over lung area. Total flux (photos/s) and 
average radiance (p/s/cm2/sr) within ROI were quantified using Living Image.  
 
Micro PET/CT imaging and correlation with bioluminescence imaging 
Female nude mice were implanted with five million A549-luc-c8 cells per mouse as 
described above (n=4). Tumor-bearing mice were first imaged in the in vivo bioluminescence 
imaging system (IVIS-Kinetic, Perkin-Elmer, Inc.) using the protocol described earlier. 
MicroPET imaging was then performed on the same day on those animals using a small 
animal PET/CT scanner (eXplore Vista, GE Healthcare, Inc., Waukesha, Wisconsin) with a 
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center resolution of 1.2 mm. Animals were anesthetized by isofluorane mixed with oxygen.  
[18]F-Fluorodeoxyglucose (FDG) with an average dose of 7.2MBq was injected through the 
tail vein catheter. A CT scan was first acquired for anatomical localization and subsequent 
attenuation correction. PET acquisition was started at 30 min after FDG injection and 
continued for 10 min. The bioluminescence and PET imaging were repeated on the same 
animal every week for at least four weeks. Raw PET data were reconstructed using 2D 
ordered subset expectation maximization algorithms with scatter, random, and attenuation 
correction using the manufacturer proprietary software. A standardized uptake value (SUV) 
was calculated based on the injection dose and animal body weight. Regions of interest 
(ROI) were manually drawn on the registered CT images along the rib cage to include the 
majority of the lung but exclude heart tissue. Mean SUVs of the lung ROI at different time 
points were reported, and compared to total flux (photos/s) of bioluminescence from the 
same mice. 
 
Histology Staining 
At the time of sacrifice, various organs (lungs, heart, liver, spleen, kidney, brain) 
from the mice were harvested and fixed in 10% formalin. After paraffin embedding, 
Hematoxylin & Eosin (H&E) staining, Masson’s Trichrome staining, or 
immunohistochemistry staining were performed for 4 µm sections. Primary antibodies in 
immunohistochemistry were bs-0657R (BIOSS) for MRP1, bs-0661R (BIOSS) for LRP, bs-
0653R (BIOSS) for Pgp, and AB8902 (Millipore) for GST-π. All histological staining was 
performed by the Animal Histopathology Core at UNC-Chapel Hill. Microscopic 
observations were carried out with Olympus Bx-61 in Microscopy Services Laboratory at 
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UNC-Chapel Hill. In the efficacy study, immunohistochemistry staining was performed for 
both the untreated original tumors in the control group and the relapsed tumors in the two 
treatment groups. Image Pro Plus was used to quantify protein expression levels. Five images 
were randomly taken for each mouse, and the average expression levels were used for further 
comparison. 
 
Preparation and characterization of BTM NPs with Br-C16-DX  
As previously reported, Br-C16-DX was synthesized from DX (Sigma-Aldrich, St. 
Louis, Missouri) to enhance lipophilicity, drug entrapment and drug retention in BTM NPs 
[134, 135]. Briefly, DX was conjugated with 2-bromohexadecanoic acid (Sigma-Aldrich, St. 
Louis, Missouri) via a one-step esterification reaction. The product was purified by 
preparative TLC, and confirmed by NMR and mass spectrometry [135].  
NPs with Br-C16-DX were prepared from a warm oil-in-water microemulsion 
precursor developed and reported previously with Brij 78, Vitamin E TPGS and Miglyol 808, 
and abbreviated as BTM NPs [136-138]. Particle diameter and zeta potential of the NPs were 
characterized as previously reported [132]. Drug entrapment efficiency was determined by 
size exclusion chromatography with Sepharose CL-4B, and the Br-C16-DX concentration 
was quantified by HPLC [135]. 
 
Efficacy study with Taxotere and Br-C16-DX NPs 
Five million A549-luc-c8 cells were implanted by dorsal side injection on day 0 as 
described above. Taxotere at 16 mg/kg or the Br-C16-DX NPs at 56 mg/kg of the conjugate 
(established maximum tolerated dose, MTD) were injected through the tail vein starting on 
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day 5. Six weekly injections were performed on day 5, 12, 19, 26, 33 and 40. Weekly whole-
body bioluminescence imaging was performed from day 0 through the end of the study. After 
mice were sacrificed, tissues were fixed in formalin for histological examination as described 
above. 
 
Statistical Analysis 
Student’s t-test was performed for two-group comparison, and Log-rank Test was 
performed for survival comparison (Prism, Version 5.01, GraphPad Software Inc., La Jolla, 
CA, USA). Differences were considered statistically significant when p < 0.05.  
 
4.  Results  
4.1 Orthotopic lung tumor implantation and survival study 
Luciferase-expressing A549-luc-c8 cells were used to establish orthotopic lung tumor 
model since luminescence signal allowed for injection verification as well as semi-
quantification of tumor size and growth pattern. In vitro characterization proved a linear 
relationship between quantified luminescence level and cell number (Figure 2.1, R2 0.9976), 
which provided a basis for utilizing bioluminescence level to monitor in vivo tumor growth. 
The tumor implantation procedure is shown in Figure 2.2A. After a mouse was 
anesthetized, a 5 mm incision was made on dorsal side over left lung. A549-luc-c8 cells 
suspended in matrigel/PBS were injected into the left lung parenchyma to a depth around 3 
mm. Once the needle was removed, the wound was closed with a skin clip and the mouse 
was laid on a heating pad until fully recovered from anesthesia. A survival study with 34 
nude mice was carried out to validate this tumor implantation method on a large animal set. 
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With the dorsal side injection technique, surgery mortality was 0% and lung tumor 
development rate was as high as 94%.  
In studies investigating drug delivery system for cancer therapy, reasonable survival 
time in the mouse model needs to be tuned and validated. In a study by Madero-Visbal et al., 
it was reported that the median survival with one million A549 cells per mouse was around 
60 days [139]. In current studies, we increased the number of cells injected to five million 
cells per mouse, which resulted in a median survival of 32 days (Figure 2.2B). Quantified in 
vivo bioluminescence increased in the beginning as tumor cells grew, then plateaued, 
followed by a continuous increase until sacrifice. The “increase - decrease or plateau – 
continuous increase” pattern of bioluminescence level was observed repeatedly in all studies 
performed with this model. Lungs were harvested and gross images are shown in Figure 
2.2C. Unlike a healthy lung with smooth surface, tumor-bearing lungs showed the presence 
of apparent disorganized tumor tissues.  Pleural effusion was often observed in tumor-
bearing lungs at the time of sacrifice.  
 
4.2 Histology characterization of the A549-luc-c8 tumor  
H&E staining (Figure 2.3A-D) and Masson’s Trichrome staining (Figure 2.3E-H) 
were performed in formalin-fixed tissues to further confirm tumor growth in the lung. 
Healthy lungs were well organized with single-cell-layer alveoli, which provided large 
surface area for air exchange and normal lung function. In contrast, tumor-bearing lungs 
presented disrupted alveolar structure, and tumor cells with large, pale nuclei. Immune cell 
infiltration and excess fibrin production in extracellular matrix were also observed in tumor-
bearing lungs, which further compromised lung function. In Masson’s Trichrome staining, a 
46 
large amount of blue collagen was seen in tumor-bearing lungs but not healthy lungs, 
reflecting fibrosis during tumor growth.  
 The orthotopic lung tumor model was characterized for drug resistance due to its 
importance in responses to chemotherapy. Several resistance-related proteins including 
MRP1, Pgp, LRP and GST-π were stained by immunohistochemistry. MRP1 and Pgp are 
efflux transporters of the ATP-binding cassette protein superfamily, which utilize energy 
from ATP hydrolysis to transport toxins or drugs out of the cell. LRP is a membrane 
transporter not belonging to the ATP-binding cassette superfamily. GST-π is a transferase 
involved in drug detoxification pathway. As shown in Figure 2.3I-L, expressions of GST-π, 
MRP1 and LRP, but not Pgp, were observed.  
 
4.3 Micro PET/CT Imaging 
Micro PET/CT imaging was performed in addition to 2D optical bioluminescence 
imaging (BLI) to obtain accurate 3D quantification in terms of tumor formation and 
metabolic activity.  As shown in Figure 2.4 upper panel, abnormal neoplasma in the lung 
was shown by CT since day 21. Increasing FDG uptake signal in the lung was observed 
overtime (middle panel), indicating increased glucose metabolic activities due to tumor 
growth. Lymph nodes had high FDG uptake on day 41, implying metastasis of tumor cells. 
Weekly bioluminescence and PET imaging were performed for more than four weeks and the 
quantified signals are provided (Figure 2.4, lower panel). Bioluminescence did not change 
significantly from day 7 to day 14 and subsequently increased overtime, while a continuous 
increase was observed in PET imaging from day 7 to day 42. The relatively comparable BLI 
signals on day 7 and day 14 are likely attributable to tissue attenuation of bioluminescence 
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signal and possible formation of a necrotic center in the tumor. Correlation between FDG 
SUV in the lung from PET images and the bioluminescence photon level in the lung from the 
same mouse was assessed (Figure 2.4, lower panel). A strong linear correlation was 
observed for quantified SUV and bioluminescence levels from four different mice over more 
than four weeks (R2 = 0.86). This correlation not only helped to validate the orthotopic model 
but also supported the use of BLI to monitor tumor growth and therapeutic response over 
time in the efficacy studies.  
 
4.4 Preparation and Characterization of BTM NPs Containing Br-C16-DX 
Br-C16-DX (Figure 2.5) was synthesized as previously described.[135]  The long 16-
carbon chain increases the solubility of the conjugate in the oil core of the NPs, and the 
bromine (Br) atom at the 2-position of the fatty acid chain leads to faster hydrolysis kinetics 
to release docetaxel. As previously reported, the Br-C16-DX NPs had a drug entrapment of 
56.8 ± 2.8%, mean particle diameter of 210 ± 2.15 nm, and zeta potential of –5.52 ± 0.97 mV 
in 0.01 molar phosphate buffered saline [135]. In vitro release studies of Br-C16-DX NPs 
were performed in 100% mouse plasma. An initial 40-45% burst release of Br-C16-DX was 
observed within 1 hr with little or no additional release over the next 8 hr [135]. 
 
4.5 In vivo anti-tumor efficacy 
The therapeutic efficacy of Br-C16-DX NPs was evaluated in the A549-luc-c8 
orthotopic lung tumor mouse model. Taxotere (16 mg/kg) or Br-C16-DX NPs (56 mg/kg of 
Br-C16-DX) was administered intravenously at predetermined MTD starting day 5 post-
tumor implantation. The control group was left untreated (n = 9 in each group). Similar to the 
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survival study, the average bioluminescence in the control group increased in the beginning, 
and then decreased, followed by a continuous increase (Figure 2.6). Bioluminescence 
imaging analysis showed significantly lower luminescence levels in the Br-C16-DX NPs 
treatment group as compared to the control untreated group starting at day 13. The 
luminescence intensity in the Taxotere group reached significantly lower levels as compared 
to the untreated group one week later, at day 20. Furthermore, the average luminescence 
level on day 20 in the NPs group was significantly lower than that in the Taxotere group 
(1.25E+5 versus 4.70E+5 p/s/cm2/sr, p < 0.05).  
Representative bioluminescence images for individual mouse are shown in Figure 
2.6C-G. For the majority of mice, luminescence signals were detected in a small region 
limited to left lung on day 0 after tumor implantation. On day 5 when treatment was started, 
tumor cells had spread to a larger area. On day 20, mice in the untreated group had developed 
very strong luminescence signals, while mice in the Taxotere and NPs groups had 
significantly lower luminescence levels, with the NP group exhibiting the lowest. The last 
treatment was administered on day 40 in accordance with the clinical treatment regimen of 
six weekly i.v. injections. Both the NPs and Taxotere groups showed baseline luminescence 
intensity levels indicating very little tumor burden. With no further treatment, the Taxotere-
treated group was progression free until ~ day 70, after which tumors relapsed as indicated 
by an increase in the luminescence intensity. In contrast, tumors in the NP-treated group 
relapsed only until after day 105.  
Interestingly, relapsed tumors in both treatment groups followed the same “increase – 
decrease or plateau - increase” growth pattern as untreated tumors. In the second increase 
phase, increasing luminescence was accompanied with significant weight loss and breathing 
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difficulty, which required that mice be sacrificed according to protocol. Expression levels of 
MRP1, LRP, Pgp, GST-π of relapsed tumors in the two treatment groups were quantified and 
compared to that of the original tumors in the untreated group. Expression levels of MRP1, 
LRP and GST-π in relapsed tumors were all significantly greater than that in untreated 
tumors (Figure 2.7), which could indicate acquired drug resistance after treatment. 
As shown in Figure 2.6B, the control group had a median survival of 41 days, which 
was significantly improved by Taxotere treatment to 131 days. Survival by treatment with the 
Br-C16-DX NPs was further enhanced to a median survival of 158 days. The improvements 
were statistically significant as compared to the control group (p<0.05 in Log-rank Test). 
Improved progression free survival and median survival in the NPs group suggest prolonged 
systemic circulation and increased tumor accumulation of the Br-C16-DX NPs, as 
demonstrated in previous pharmacokinetic studies [135]. For both treatment groups, 55.6% 
of the mice had been sacrificed at 158 days after tumor implantation. At this point, the study 
was terminated as the remaining mice in each group had baseline levels of bioluminescence 
intensity. Lungs from these surviving mice were harvested and fixed in formalin. Gross 
images and H&E staining showed smooth surface and mostly normal lung histology with 
organized alveoli (Figure 2.8). Metastasis was shown by positive luminescence in distant 
tissues only in the control group with a rate of 11.1% (Figure 2.9). Histology examination 
proved tumor growth in lymph nodes and major organs including heart, liver, kidney and 
brain. This is likely due to the spread of cancer cells to other distant organs through lymph 
nodes. 
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5.   Discussion  
In these current studies, a clinically-relevant orthotopic NSCLC model was 
established in nude mice. This model was shown to be feasible and reproducible using the 
dorsal side injection technique, with 94% lung tumor development rate and 0% surgery 
mortality. The Br-C16-DX NPs previously developed in our laboratory were investigated in 
this model and shown to have superior therapeutic efficacy over commercial Taxotere.  
At early stage of model development, we investigated an intrabronchial injection 
protocol with a 1.2 cm needle reported by McLemore et al. [122]. After nasal luminescence 
was observed following injection, the original method was refined by utilizing a one inch 
blunted needle that was inserted deeper into trachea to allow the tumor cells to reach the lung 
instead of resulting in nasal deposition due to normal breathing patterns of the mouse. 
However, this method had surgery mortality of 13% during intrabronchial injection (n = 15). 
Furthermore, with A549-luc-c8 cells implanted in the lung as confirmed by bioluminescence 
imaging, lung tumor was successfully developed in only 47% of the mice three weeks post-
injection. Either luminescence signal in trachea or no luminescence was observed in 40% of 
the mice. Tumor growth in upper airway is difficult to avoid with intrabronchial injection. 
Zou et al. observed tumors in bronchus and neck despite careful withdrawal of the needle, 
and bathing the wound in 70% ethanol after injection [123]. A Lung tumor developed in only 
two out of five mice in their studies.  
Intrabronchial injection requires high level surgical skills and specialized devices 
such as a surgical board and modified needles, which lead to lack of reproducibility of the 
injection technique and compromised lung tumor development rate [140, 141]. Mice needed 
to be maintained in a reverse Trendelenburg maneuver using the McLemore protocol to keep 
51 
tumor cells in the distal airways of the right lung, which requires the use of surgical board 
and full restraint of all limbs. Vertrees et al. held the mice in a head-up position, and utilized 
a homemade endotracheal tube, a homemade laryngoscope, together with a piece of PE 50 
tubing for cell injection [140]. Kang et al. reported intrabronchial injection with a needle bent 
to 135° angle. The lung tumor development rate was only 20% even with A549 cells taken 
from in vivo subcutaneous passaging in nude mice [141]. However, the simultaneous 
administration of EDTA improved the lung tumor development rate to 80% in their studies, 
presumably due to slight disruption of the lung parenchymal epithelium and surfactant layer.  
Due to surgery complexity and unsatisfactory lung tumor growth, we later 
investigated tumor injection directly through left chest wall. With an incision on the left 
chest, cell suspensions were injected directly into the left lung parenchyma (n = 25). 
Subsequent whole-body bioluminescence imaging revealed abdominal luminescence in 20% 
of the mice likely due to heart puncture during injection (Figure 2.10). For some mice with 
luminescence only in the lungs, positive luminescence was observed in the heart when organs 
were imaged following autopsy. Lung tumor development rate by this direct chest injection 
method was 72%.  
To overcome above limitations, the surgical technique was modified wherein the cells 
were injected from dorsal side over the left lung. Using this modification, the heart was better 
protected from injection contamination since the injection site was further away (Figure 
2.10). Abdominal luminescence was observed occasionally but at much lower rate. In a 65-
mice study using this dorsal injection technique, abdominal luminescence was observed in 
only two mice (3%). Chest cavities were imaged following injection, and were proved to be 
clean (data not shown). Lung tumor development rate was greater than 90% and surgery 
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mortality was 0% in all studies with dorsal side injection. Furthermore, model establishment 
was easily feasible and very reproducible. Mice could be simply laid on their abdomen 
during injection with no need to restrain mice or to position them with any special devices or 
equipment.  
An “increase - decrease or plateau – continuous increase” pattern for in vivo 
bioluminescence was observed repeatedly in the developed model with A549-luc-c8 cells. 
Similar trend has been observed with intravenous injection of the same cell line into the 
lungs of SCID mice [142]. The decrease or plateau phase could be partially attributable to the 
tissue attenuation of bioluminescence signal rising from the deep tissue, resulting in 
unproportional increase of signal with the tumor growth. As shown in Figure 2.4 (lower 
panel),  day 7 and day 14 had increasing PET SUV but relatively comparable 
bioluminescence signal likely due to tissue attenuation in BLI. It is notable that although the 
correlation between BLI and PET was slightly off at lower signal range, a strong linear 
correlation was observed overall (R2 = 0.86). Another potential cause of the plateau phase is 
a necrotic formation typically in the center of the tumor due to insufficient nutrition supply. 
In a study with subcutaneous A549 tumor, Ahmed et al. observed an increase in tumor 
volume followed by a plateau around day 22 to day 25, and then continuous increase 
afterwards [143]. Since tumor volume is measured by geometrical dimensions in 
subcutaneous model where tissue attenuation is not a concern, this plateau phase could be 
mainly caused by the formation of a necrotic center in the tumor.  
Orthotopic lung tumor growth and lymph node metastasis were shown by increased 
FDG uptake in PET imaging. The mean SUV of the lung lesion reported here is slightly 
lower as compared to that in subcutaneous A549 model [144-146]. This is mainly due to the 
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different approach in defining regions of interest in mean SUV measurement. ROI in 
subcutaneous model only includes tumor tissue, while in our study, due to multiple tumor 
nodules and small volume in earlier stage, the ROI was defined as the whole lung including 
tumor tissue and healthy lung tissue, resulting in lower SUV in average. On the other hand, 
different growth environment in orthotopic model could potentially play a role and lead to 
the different tumor metabolism level as compared to the subcutaneous counterpart. 
Compared to the results from the subcutaneous tumor model, the FDG PET imaging in the 
orthotopic NSCLC model revealed more heterogeneity of FDG uptake, with SUV ranging 
from 0.5 to 7.3, and average SUV (max) of 4.07+/- 1.2.  The PET imaging results in the 
orthotopic model agree with the imaging pattern of human NSCLC with large heterogeneity 
and high SUV (max) reported in the clinic [147].  
The in vivo efficacy study showed that Br-C16-DX NPs provided a greater 
therapeutic benefit than Taxotere in the A549-luc-c8 orthotopic lung tumor model. The NP-
treated group exhibited delayed tumor relapse from 70 to 105 days, and prolonged median 
survival from 131 to 158 days as compared to the Taxotere group. These results suggest 
prolonged systemic circulation and increased tumor accumulation of the Br-C16-DX NPs as 
was previously established with this Br-C16-DX NP formulation in a subcutaneous breast 
cancer model [135]. For intravenously administered Taxotere or Br-C16-DX NPs, both at a 
DX dose of 10 mg/kg, the plasma AUC0-∞ of NP-formulated Br-C16-DX was 100-fold 
greater than that of Taxotere, and terminal half-life 8.7-fold greater. The DX AUC 
hydrolyzed from Br-C16-DX was improved by 4.3-fold as compared to Taxotere, and mean 
resonance time improved by 6.4-fold.  Furthermore, PK/biodistribution studies of BTM NPs 
with a drug conjugate were performed in the developed orthotopic NSCLC model. The 
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plasma half-life of the drug conjugate from BTM NPs was 9.9-fold greater than free drug, 
producing a 23.5-fold higher dose-normalized AUC0-96h in plasma. In addition, the dose-
normalized AUC0-96h of the drug conjugate in tumor-bearing lungs was 13.8-fold greater than 
free drug. These results demonstrated that BTM NPs significantly prolonged circulation time 
and increased drug exposure of the delivered drug to the target tissue.  
The linear correlation between BLI and PET (Figure 2.4, R2 = 0.86) in the orthotopic 
NSCLC model supported the use of BLI to monitor tumor growth and to compare different 
treatment groups and their response. BLI is also more time- and cost-effective than PET. In 
the efficacy study, bioluminescence from A549-luc-c8 provided a reliable signal for tumor 
growth up to more than 150 days. In the untreated group, both primary tumor growth and late 
stage metastasis to lymph nodes were identified by positive bioluminescence signal. In both 
treatment groups, suppression of original tumors, progression-free period, and tumor relapse 
were shown by a decrease in luminescence to nearly baseline levels followed by an increase 
in the luminescence upon tumor regrowth.  Further, histological examination after autopsy 
supported the imaging results.  
Expression levels of drug resistance-related proteins were significantly greater in 
relapsed tumors as compared to untreated tumors. Nanomedicines have the potential to 
overcome drug resistance through inhibition of drug efflux transporters, receptor-mediated 
endocytosis, or unclear mechanisms [148-150]. Specifically, BTM NPs have been previously 
proven to inhibit Pgp and deplete ATP [151]. Br-C16-DX NPs to treat resistant lung tumor 
could be further investigated. 
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Figure 2.1 In vitro bioluminescence imaging of A549-luc-c8 cells 
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Figure 2.2 Orthotopic lung tumor implantation and survival study. (A) Dorsal side lung 
tumor implantation procedure as shown in three panels. (B) Survival curve (left y-axis, 
circle) and whole-body bioluminescence monitoring (right y-axis, triangle) in survival study 
(n=34). (C) Gross images of tumor-bearing lungs with disorganized tumor tissue.  
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Figure 2.3 Histology characterization of orthotopic lung tumors. (A-D) H&E staining of 
healthy lung (A) and tumor-bearing lungs (B, C, D). Alveoli structure in tumor-bearing lung 
was disrupted by immune cell infiltration (C) and tumor cells (D). (E-H) Masson’s 
Trichrome Staining. (E) and (F), healthy lung tissue with little collagen. (G) and (H), tumor-
bearing lung with large amount of blue collagen due to fibrosis during tumor growth. (I-L) 
Immunohistochemistry for MRP1 (I), LRP (J), GST-π (K) and Pgp (L). Scale bar, 120 µm.  
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Figure 2.4 Micro PET/CT imaging and correlation with  bioluminescence imaging. Upper 
panel, CT imaging of the same mouse from day 7 to day 42. Middle panel, PET/CT overlay 
with an arrow in day 42 image indicating high FDG updake in lymph nodes. Lower panel, 
quantified signal from bioluminescence imaging (BLI, left), FDG PET imaging (middle), and 
the correlation of these two imaging approaches (right, R2 = 0.86). 
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Figure 2.5 Structure of Br-C16-DX 
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Figure 2.6 Efficacy study with Taxotere (16 mg/kg) and Br-C16-DX NPs (56 mg/kg). 
Weekly i.v. injections were administered from day 5 to day 40. (A) Quantified average 
luminescence levels in control (black filled circles), Taxotere (blue square) and NPs group 
(red triangle). Red asterisk, NPs group vs. control group on day 13, p < 0.05. Blue asterisk, 
Taxotere group vs. control group on day 20, p < 0.05. +, NPs group vs. Taxotere group on 
day 20, p < 0.05. Error bar, standard error of the mean. (B) Survival curve. Tail vein 
injections are indicated by the arrows. (C) Representative whole-body bioluminescence 
image on day 0. (D) Representative bioluminescence image on day 5. (E-G), representative 
bioluminescence images on day 20 in control (E), Taxotere (F), and NP group (G).  
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Figure 2.7 Immunohistochemistry quantification of resistance-related proteins. Images of 
MRP1 (A), LRP (B), GST-π (C), and Pgp (D) in relapsed tumors in Taxotere or NP-treated 
groups; scale bar, 60 µm. Positive staining (LRP, MRP1 and GST-π) was quantified by 
Image Pro Plus. Relapsed tumors had significantly greater MRP1, LRP and GST-π 
expressions than untreated tumors (p = 0.0043 for LRP, p = 0.0058 for MRP1 and p < 0.0001 
for GST-π in student t-test
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Figure 2.8 Gross images and H&E staining of lungs from surviving mice in two treatment 
groups. Scale bar, 60 µm. 
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Figure 2.9 Metastasis in control group of the efficacy study. A and B, whole-body 
bioluminescence images on day 0 (A) and day 41 (B) after tumor implantation. C-G, H&E 
staining of lymph node (C), brain (D), heart (E), liver (F) and kidney (G) after the mouse 
was sacrificed (same magnification). Tumor cells were indicated by arrows. Scale bar, 60 
µm. 
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Figure 2.10 Comparison of chest wall injection and dorsal side injection. (A) Anatomy of a 
nude mouse showing that the left lung is partially blocked by the heart for the chest wall 
injection. (B) Anatomy of a nude mouse showing no blockage of the lung in the dorsal side 
injection. (C) Chest Wall Injection: abdominal luminescence was observed in 20% of the 
mice likely due to heart puncture. (D) Chest Wall Injection: for some mice with no 
abdominal luminescence in chest wall injection, when the hearts and lungs were taken out 
and imaged after tumor implantation, luminescence signal was seen in both hearts and lungs 
in three out of four mice.  (E) Dorsal Side Injection:  the bioluminescence signal was only 
observed in lungs but not hearts. 
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CHAPTER 3. 
2’-(2-BROMOHEXADECANOYL)-PACLITAXEL CONJUGATE 
NANOPARTICLES FOR THE TREATMENT OF NON-SMALL CELL LUNG 
CANCER IN AN ORTHOTOPIC XENOGRAFT MOUSE MODEL 
 
1. Summary  
A nanoparticle (NP) formulation with 2’-(2-bromohexadecanoyl)-paclitaxel (Br-16-
PX) conjugate was developed in these studies for the treatment of non-small cell lung cancer 
(NSCLC). The lipophilic paclitaxel conjugate Br-C16-PX was synthesized and incorporated 
into lipid NPs to improve drug entrapment in the drug delivery system and to enhance in vivo 
pharmacokinetics and conversion to paclitaxel (PX) at the tumor site. The developed system 
was evaluated in luciferase-expressing A549 cells in vitro and in an orthotopic NSCLC 
mouse model. The results demonstrated that the Br-C16-PX NPs had a greater maximum 
tolerated dose (MTD, 75 mg/kg) as compared to Taxol® (19 mg/kg). Furthermore, longer 
half-life and significantly enhance area under the curve both in plasma and in tumor-bearing 
lungs were observed in pharmacokinetic studies. The Br-C16-PX conjugate was converted to 
the parent drug PX primarily in tumor and pleural fluid. The Br-C16-PX NPs at MTD 
significantly prolonged median survival (88 days, p = 0.03) as compared to the Taxol-treated 
group at MTD (70 days) in the orthotopic mouse model with advanced NSCLC.  
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2. Introduction  
Lung cancer is the leading cause of cancer mortality worldwide. An estimated 
228,190 new cases and 159,480 deaths of lung cancer are expected in 2013, accounting for 
14% of cancer diagnosis and 27% of all cancer deaths, respectively [152]. Lung cancer 
survival is largely related to cancer stage at the time of diagnosis. The five-year survival is 
52.6% for localized lung cancer and only 3.5% for patients with the presence of distant 
tumors at diagnosis [119]. Among all lung cancer cases, 84% are classified as non-small cell 
lung cancer (NSCLC) and 15% as small-cell lung cancer for the purpose of treatment. The 
microtubule stabilization agent paclitaxel (PX) is used either as a monotherapy or in 
combination with carboplatin for the treatment of NSCLC [127].  
Currently PX is commercially marketed as Taxol and Abraxane. Taxol contains 
Cremophor EL and dehydrated ethanol as co-solvents to solubilize paclitaxel and was given 
approval by the FDA in 1992. However, the hydrophobic nature of paclitaxel requires the 
amount of co-solvents to be so high that serious side effects including anaphylaxis and severe 
hypersensitivity are unavoidable. Premedication with corticosteroids, diphenhydramine, and 
H2 antagonist is required prior to Taxol administration to prevent severe hypersensitivity 
reactions but fatal reactions could still occur despite pretreatment.  
Abraxane, an albumin-bound paclitaxel NP (mean diameter 130 nm), was approved 
by the FDA in October 2012 for the first-line treatment of non-small cell lung cancer 
(NSCLC) in combination with carboplatin. In the phase III trial CA-031, weekly albumin-
bound paclitaxel (nab-PX) plus carboplatin was compared with solvent-based paclitaxel (sb-
PX) plus carboplatin in advanced NSCLC patients [4]. Nab-PX exhibited decreased 
neuropathy and neutropenia likely due to the absence of toxic excipients. However, more 
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thrombocytopenia and anemia were observed in patients treated with nab-PX as compared to 
patients treated with sb-PX. Furthermore, the 10% improvement of progression-free survival 
(p = 0.21) and overall survival (p = 0.27) were not statistically significant. The response rate 
was increased only for squamous cell carcinoma and large cell carcinoma, but not for 
adenocarcinoma. Moreover, although Abraxane exhibited linear thus more predictable 
pharmacokinetic profile, the half-life (p = 0.48) and area under the concentration versus time 
curve (AUC, p = 0.52) of Abraxane at 260 mg/m2 were not significantly increased as 
compared to Taxol at 175 mg/m2 [5]. Therefore, a PX formulation with decreased toxicity, 
improved therapeutic index and better pharmacokinetic property is needed.  
Nano-formulations of PX have been investigated for safer and more effective 
chemotherapy [153-156]. However, most nano-systems are limited by moderate drug 
solubility or rapid drug release when administered in vivo. Previously, our laboratory 
synthesized a 2’-benhenoyl-paclitaxel conjugate (C22-PX) to increase the lipophilicity of PX 
in the Miglyol oil core of the lipid-based NPs. The solubility of C22-PX was increased to 15-
25-fold in different Miglyols as compared to that of PX, and the C22-PX NPs were shown to 
have significantly improved antitumor efficacy in a subcutaneous 4T1 mouse mammary 
carcinoma model [138].  
Despite enhanced lipophilicity, a common problem with taxane derivatives is the 
compromised cytotoxicity due to suboptimal conversion of these conjugates to release the 
more effective parent drug. As reported previously, only 5-7% PX was derived from free 
C22-PX or C22-PX NPs after 48 hr incubation in 4T1 tumor homogenate at 37°C [138]. To 
overcome this limitation, a 2’-(2-bromohexadecanoyl)-paclitaxel (Br-16-PX) conjugate was 
synthesized in current studies, where the electron-withdrawing bromine (Br) group at the 2’-
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position of the fatty acid chain facilitates faster hydrolysis to release PX. The Br-C16-PX 
conjugate was then incoporated into lipid-based NPs which were further evaluated for the 
treatment of NSCLC.  
In vivo performance of the Br-C16-PX NPs was evaluated in an orthotopic NSCLC 
mouse model previously established and characterized in our laboratory [157]. To mimic the 
therapy of advanced NSCLC, the treatment was started later than 50% of the median survival 
in current studies. The Br-C16-PX NPs were shown to have superior therapeutic efficacy and 
improved pharmacokinetic properties as compared to Taxol in the orthotopic xenograft 
model.   
 
3. Materials and Methods 
Materials 
Polyoxyl 20-stearyl ether (Brij 78) was purchased from Uniqema (Wilmington, 
Delaware). D-alpha-tocopheryl polyethylene glycol-1000 succinate (Vitamin E-TPGS) was 
purchased from Eastman Chemicals (Kingsport, Tennessee). Miglyol 812 was purchased 
from Sasol (Witten, Germany). PX powder was bought from LC Laboratories (Woburn, 
Massachusetts). Taxol was purchased from Hospira Inc. (Lake Forest, IL). Sodium fluoride, 
2-bromohexadecanoic acid and 4-dimethylaminopyridine (DMAP) were purchased from 
Sigma (St. Louis, Missouri). Sepharose CL-4B was acquired from GE Healthcare (Uppsala, 
Sweden). The tubulin polymerization assay kit was purchased from Cytoskeleton Inc. 
(Denver, Colorado). D-luciferin potassium salt and Caliper IVIS Lumina II were from 
Caliper (Hopkinton, Massachusetts). RPMI 1640 and DPBS were purchased from Invitrogen 
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(Carlsbad, California). Fetal bovine serum (FBS) was purchased from ATCC (Manassas, 
Virginia). Matrigel was obtained from BD Biosciences (San Jose, California).  
 
Optimization and characterization of Br-C16-PX NPs 
Br-C16-PX was synthesized as previously reported [30]. Briefly, PX was conjugated 
with 2-bromohexadecanoic acid via a one-step esterification reaction with DMAP as the 
catalyst. The product was purified by preparative TLC, and the structure and molecular mass 
confirmed by NMR and mass spectrometry [30]. 
Our laboratory has previously prepared PX BTM NPs from a warm oil-in-water 
microemulsion precursor with Brij 78 and TPGS as surfactants and Miglyol 812 as the oil 
phase (abbreviated as “BTM” NPs) [136, 137]. For the current formulation with Br-C16-PX, 
the system was optimized by decreasing the amount of surfactants while enhancing drug 
loading and drug entrapment. The particle diameter of the NPs was measured using a Coulter 
N5 Plus Sub-Micron Particle Sizer (Beckman Coulter, Florida). The drug entrapment 
efficiency was determined by gel permeation chromatography (GPC) with Sepharose CL-4B. 
Briefly, the NPs were loaded onto a 15-cm GPC column, and fifteen fractions were collected 
(1 ml per fraction) via PBS elution. Light scattering intensity of each fraction was determined 
with a N5 Particle Sizer. Br-C16-PX concentration was determined by HPLC (γ = 230 nm) 
with an Intersil ODS-3 column (4.6 × 150 mm, 4 µm particle size, GL Sciences Inc.) and a 
mobile phase consisting of acetonitrile/water/isopropanol (55:10:35, v/v/v) with a flow rate 
of 1 ml/min. 
For in vivo studies in nude mice, the Br-C16-PX NPs were pegylated by adding 0.2 
mg/ml Brij 700 during the preparation.  
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Tubulin polymerization activity of Br-C16-PX 
Tubulin polymerization activity of Br-C16-PX was evaluated using a tubulin 
polymerization assay kit. The standard (control) polymerization condition includes 3 mg/ml 
tubulin in 80 mM PIPES buffer at pH 6.9 in the presence of glycerol. PX at 10 µM was used 
as the positive control, and Br-C16-PX was evaluated at 10 µM and 34 µM. The reaction was 
conducted at 37°C and the degree of tubulin polymerization was quantified by the change in 
absorbance at 340 nm. The OD340 nm was monitored with a Synergy 2 Multi-Detection 
Microplate Reader (BioTek, Winooski, Vermont) over a 60 min period with 1 reading per 
min. The maximum rate of tubulin polymerization (Vmax, mOD/min) was plotted for each of 
the control, PX 10 µM, Br-C16-PX 10 µM, and Br-C16-PX 34 µM groups.  
 
Cell Culture  
Luciferase-expressing human lung adenocarcinoma cell line A549-luc-c8 (Caliper, 
Hopkinton, Massachusetts) was maintained in RPMI 1640 medium supplemented with 10% 
FBS and antibiotic. Cells were cultured in a humid incubator with 5% CO2 at 37°C. 
 
Cytotoxicity of Br-C16-PX  
The cytotoxicity of Br-C16-PX in A549-luc-c8 human lung adenocarcinoma cells 
was determined using a 3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) assay and compared to PX. Briefly, A549-luc-c8 cells were cultured as described 
above and seeded in a 96-well plate with 5,000 cells/100 µl growth medium per well. PX, Br-
C16-PX NPs, or blank NPs without Br-C16-PX were added to the plate at a series of 
different concentrations. After 48 hr incubation at 37 °C, the cells were incubated with MTT 
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solution for another 3 hr. Lastly, DMSO was added to solubilize the converted dye, and the 
absorbance at 570 nm was measured with a Synergy 2 Multi-Detection Microplate Reader. 
The IC50 of the drug (the concentration that leads to 50% cell survival inhibition) was 
determined from survival plots.  
 
Orthotopic lung tumor implantation  
Four to six week old female nude mice (Harlan Sprague Dawley) were housed in a 
pathogen-free room. Orthotopic lung tumor was implanted as previously reported [157].  
Briefly, after mice were anesthetized, a 5 mm incision was made on the dorsal side over left 
lung. Fat and muscles were separated to visualize lung movement. Five million A549-luc-c8 
cells suspended in 40 µl PBS/matrigel were injected directly into the left lung parenchyma at 
a depth of 3 mm. All mouse studies were conducted according to a protocol approved by the 
University of North Carolina Institutional Animal Care and Use Committee.  
 
Whole-body bioluminescence imaging  
Weekly whole-body bioluminescence imaging was performed in mouse studies to 
monitor orthotopic lung tumor growth. D-luciferin potassium salt reconstituted in DPBS was 
injected intraperitoneally at 150 mg/kg. Mice were anesthetized with 2% isoflurane and 
imaged by Caliper IVIS Lumina II fifteen minutes after luciferin injection.  
 
In vivo antitumor efficacy studies  
A549-luc-c8 cells were implanted into the left lung of nude mice on day 0 as 
described above. Mice were randomized into 4 groups (9 mice / group): control group 
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(untreated), Taxol at 19 mg/kg (established MTD), Br-C16-PX NPs at 60 mg/kg (“NP 60 
group”), and Br-C16-PX NPs at 75 mg/kg (“NP 75 group”). Treatments were started as i.v. 
injections on day 16 with the treatment schedule of Q7d × 6. Mice were sacrificed when 
Body Condition Scoring (BCS) was 2 or less, or when a total weight loss of 20% was 
reached at any time for any mouse in the study [133].  
 
Histology staining  
The efficacy study was terminated on day 154 post tumor cell implantation, with one 
mouse living in the NP 60 group and two mice living in the NP 75 group. Lungs of the 
surviving mice were harvested. After formalin fixing and paraffin embedding, Hematoxylin 
& Eosin (H&E) staining was performed for 4 µm sections of the lungs. Histological staining 
was performed by the Animal Histopathology Core at UNC-Chapel Hill. Microscopic 
observations were carried out with Olympus Bx-61 in Microscopy Services Laboratory at 
UNC-Chapel Hill.  
 
LC-MS/MS quantification of PX and Br-C16-PX 
PX, Br-C16-PX and docetaxel (internal standard) were separated on a Waters XSelect 
CSH Phenyl-Hexyl column (2.1 × 50 mm, 130 Å pore size, 5 µm particle size) using a 
gradient mobile phase consisting of 0.1% formic acid in water (mobile phase A) and 0.1% 
formic acid and 10% isopropanol in acetonitrile (mobile phase B) on a Shimadzu LC-20AD 
liquid chromatography. The flow rate was 0.33 ml/min and the total run time was 6 minutes.  
The compounds were measured using a Thermo TSQ Ultra Triple Quadrupole Mass 
Spectrometer equipped with a heated electrospray ionization source in the positive ion mode. 
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The discharge current was held at 3.7 kV and the vaporizer temperature at 225°C.  PX, Br-
C16-PX and docetaxel were detected by selected-reaction monitoring using the transitions 
854 → 286, 1172 → 604, and 808 → 527, respectively.   
 
Pharmacokinetic and biodistribution studies 
A549-luc-c8 cells were injected into the left lung parenchyma on day 0 as described 
above. On day 16 post implantation, either Taxol at 19 mg/kg or Br-C16-PX NPs at 75 
mg/kg of the conjugate was administered as a single i.v. bolus. Mice were sacrificed at 
predetermined time points (3 mice / time point). Plasma and tissues including tumor-
containing lung, liver, spleen and kidney were harvested. Discernible lung tumor nodules 
were dissected for analysis when possible. Since pleural effusion was often observed at the 
time of sacrifice, the excess pleural fluid was collected when present. Plasma was harvested 
in sodium fluoride/ potassium oxalate blood collection tubes and tissues were homogenized 
in the presence of 2.5 mg/ml sodium fluoride to serve as an esterase inhibitor to prevent ex 
vivo conversion.  The drugs were extracted from matrix by acetonitrile with 0.1% formic 
acid. The concentrations of PX from Taxol, Br-C16-PX from the NPs, and PX converted 
from Br-C16-PX were determined by LC-MS/MS as described above. Non-compartmental 
pharmacokinetic analysis was performed using WinNonlin version 6.2.0 (Pharsight Corp., 
Cary, NC). The AUC from 0 to 96 hr (AUC0-96hr), AUC from 48 to 96 hr (AUC48-96hr), half-
life (T1/2), volume of distribution (Vd), clearance (CL), and mean residence time (MRT) were 
reported. 
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In vivo toxicity of Br-C16-PX NPs 
In vivo toxicity of Br-C16-PX NPs on liver and kidney were investigated in non-
tumor bearing nude mice. After a single i.v. injection of Br-C16-PX NPs at 75 mg/kg, whole 
blood was collected at 4 hr, 24 hr, and 48 hr post-injection. Control group was injected with 
saline. Liver function test and kidney function test were performed by the Animal Clinical 
Chemistry Core Facility at UNC-Chapel Hill.  
 
Statistical analysis 
Statistical analysis was performed with Prism (GraphPad Software Inc., La Jolla, 
California). One-way ANOVA was applied for multiple-group comparison, with Tukey's 
Multiple Comparison Test as a post-test to compare any two groups. Log-rank Test was 
performed for survival comparison. Differences were considered statistically significant 
when p < 0.05.  
 
4. Results  
4.1 Optimization and characterization of Br-C16-PX NPs 
Br-C16-PX was synthesized through the conjugation of PX and 2-
bromohexadecanoic acid as previously reported [30] (Figure 3.1). The long 16-carbon chain 
at the 2’-position improves the solubility of the conjugate in the Miglyol oil core of the BTM 
NPs while the Br atom at the 2-position is expected to enable faster hydrolysis of the 
conjugate to release PX.  
Br-C16-PX NPs were formulated using a microemulsion precursor method with 
Miglyol 812 as the oil phase, and Brij 78 and TPGS as surfactants (abbreviated as BTM NPs) 
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[136, 137]. To further optimize the Br-C16-PX NPs in terms of drug loading, drug 
entrapment and particle size, four different formulations (Formulations I - IV) of the 
conjugate were investigated with various concentrations of surfactants and Br-C16-PX 
(Table 3.1). Hydrodynamic particle diameters of all formulations were around 200 nm. Drug 
entrapment of each formulation was determined using gel permeation chromatography (GPC) 
with PBS elution. NPs of 200 nm size eluted in fractions 3-5 as monitored by light scattering 
intensity and particle size measurement. With decreasing concentrations of Brij 78 and 
TPGS, the drug entrapment of 0.5 mg/ml Br-C16-PX increased from 50.87 ± 0.01% to 70.00 
± 0.06% (Formulations I - III). In Formulation IV, Br-C16-PX concentration was increased 
to 1.0 mg/ml which yielded a drug entrapment of 66.45 ± 0.02%. Although the drug 
entrapment in Formulation IV appeared to be slightly lower than Formulation III, it was 
considered to be the optimal formulation since the drug loading capacity was as high as 40% 
(w/w, drug/oil). In contrast, previously reported PX BTM NPs and C22-PX BTM NPs had a 
drug loading of only 7.5% and 7.7% by weight, respectively [138, 151], likely due to 
relatively low affinity of PX to the Miglyol oil core in the PX BTM NPs, or excess amount of 
surfactant in the C22-PX BTM NPs.  
 
4.2 Tubulin polymerization activity of Br-C16-PX 
The principle of the tubulin polymerization assay is that the extent of light being 
scattered by microtubules is proportional to the concentration of microtubule polymer. Under 
standard assay conditions at 37°C, the tubulin polymerization process is described by an 
increasing OD340 nm curve comprised of nucleation phase, growth phase, and equilibrium 
phase. The maximum polymerization rate (Vmax) obtained from the first derivative of the 
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polymerization curve represents how fast the tubulin is polymerized under a certain 
condition. As shown in Figure 3.2A, a dose-dependent acceleration of tubulin 
polymerization was observed for Br-C16-PX. Br-C16-PX at 10 µM had a Vmax similar to the 
negative control (20.0 ± 1.4 versus 17.5 ± 2.1 mOD/min). When Br-C16-PX concentration 
was increased to 34 µM, the Vmax (30.5 ± 2.1 mOD/min) was comparable to PX at 10 µM 
(29.0 ± 0.0 mOD/min). It should be noted that the Vmax was reached later for Br-C16-PX (8-9 
min) in the 60 min time course than PX (0-3 min). 
 
4.3 Cytotoxicity of Br-C16-PX NPs 
An in vitro cytotoxicity study of free PX, blank NPs and Br-C16-PX NPs was carried 
out in the A549-luc-c8 cell line using the MTT assay. As shown in Figure 3.2B, the IC50 of 
Br-C16-PX NPs was 62.2-fold greater than free PX (5.3 ± 3.2 nM). This is expected and 
consistent with other reported studies of 2’-PX conjugate since the 2’-OH group is crucial to 
the cytotoxicity and tubulin polymerization activity of PX [6, 7, 30, 31]. The blank NPs 
didn’t show significant cytotoxicity (drug equivalent IC50 3080.5 ± 406.6 nM), indicating 
some cytotoxic effect of the Br-C16-PX conjugate. 
 
4.4 In vivo antitumor efficacy studies 
The therapeutic efficacy of Br-C16-PX NPs was evaluated in the orthotopic NSCLC 
mouse model established with A549-luc-c8 cells. Starting on day 16 post tumor cell 
implantation, Taxol at 19 mg/kg (predetermined MTD) and Br-C16-PX NPs at 60 mg/kg 
(“NP 60 group”) and 75 mg/kg (“NP 75 group”) were administered intravenously with the 
treatment schedule of Q7d x 6. As shown in Figure 3.3A, the control group had a median 
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survival of 31 days, which was improved by Taxol treatment to 70 days. A dose response 
was observed for the treatment with Br-C16-PX NPs. Median survivals for the NP 60 group 
and the NP 75 group were 77 days and 88 days, respectively. The median survival was 
significantly improved by Br-C16-PX NPs at 75 mg/kg as compared to the Taxol standard of 
care at its MTD (p = 0.03).  
The efficacy study was terminated on day 154 post tumor cell implantation, when one 
mouse in the NP 60 group and two mice in the NP 75 group were still living.  Stronger 
bioluminescence signal was observed in the lung of the surviving mouse in the NP 60 group 
(Figure 3.3B, color scale between 3.65E6 and 6.68E7). The two mice in the NP 75 group 
had little bioluminescence signal, indicating minimal tumor growth (Figure 3.3C). Gross 
images and H&E staining of the lungs harvested from the surviving mice agreed with the 
bioluminescence imaging results. The lungs of the mice in the NP 75 group had either no 
solid tumor nodule or a very small nodule in the left lung. While in the surviving mouse in 
the NP 60 group, an apparent tumor nodule occupied almost the entire lobe of the left lung.  
 
4.5 Pharmacokinetic and biodistribution studies 
Pharmacokinetic (PK) and biodistribution studies of Br-C16-PX NPs and Taxol were 
carried out in the orthotopic NSCLC model at 75 mg/kg and 19 mg/kg, respectively. Tumors 
were distributed throughout the lung in the form of multiple nodules and possibly diffuse 
cells at the time of tissue collection, which made it difficult to dissect all the tumors from the 
lung in a time-efficient manner. Therefore, tumor-containing lungs were analyzed as a whole 
in the PK/biodistribution studies. However, a number of clearly discernible lung tumors were 
successfully dissected at several time points including 5 min, 15 min, 48 hr, 72 hr and 96 hr. 
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This dissection is believed to have minimal impact on quantified drug concentrations in the 
whole tumor-bearing lungs due to the small size of the dissected tumors and relatively low 
drug concentration. Excess pleural fluid was generated due to tumor growth and was 
collected for analysis when present.  
As shown in Figure 3.4A and Table 3.2, plasma concentration of PX from Taxol 
decreased rapidly and was below the LC-MS/MS quantification range after 8 hr, while the 
concentration of Br-C16-PX was detectable up to 96 hr. The clearance and volume of 
distribution of Br-C16-PX in plasma were significantly decreased resulting in increased AUC 
and drug exposure. The clearance of Br-C16-PX from the NPs was only 4.3% of the PX 
clearance from Taxol, and the AUC0-96hr was 91.7-fold greater, suggesting prolonged 
systemic circulation of the NPs. The T1/2 (27.2 hr versus 0.8 hr) and MRT (14.5 hr versus 0.7 
hr) of PX converted from Br-C16-PX were much longer as compared to Taxol, indicating 
sustained conversion of PX from the Br-C16-PX NPs.  
Drug concentration and PK parameters in the tumor-bearing lungs are illustrated in 
Figure 3.4B and Table 3.2. Br-C16-PX had a 49.6-fold greater AUC0-96hr and longer T1/2 
(80.9 hr versus 30.3 hr) as compared to Taxol. The concentration of PX converted from Br-
C16-PX NPs reached greater numbers than Taxol at 4 hr and remained higher up to 96 hr 
with a much longer MRT (32.2 hr versus 14.7 hr). The AUC0-96hr and AUC48-96hr of PX from 
NPs were 1.1-fold and 2.7-fold greater than Taxol, respectively. The significantly increased 
and prolonged exposures of tumor-bearing lungs to both Br-C16-PX and converted PX 
contributed to superior therapeutic efficacy of the Br-C16-PX NPs over Taxol observed in 
the efficacy studies. The biodistribution of Br-C16-PX in different specimens is summarized 
in Figure 3.4C. Br-C16-PX was distributed primarily in the plasma from 5 min to 4 hr, and 
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then mainly in liver and spleen after 8 hr. Current pegylation with Brij 700 may not be high 
enough to shield the NPs from the reticuloendothelial (RES) system. Denser pegylation is 
currently being investigated to further decrease RES uptake and prolong circulation and 
ultimately increase tumor accumulation. 
Importantly, the ratio of converted PX over the conjugate for the Br-C16-PX NPs was 
greater in pleural fluid and lung tumors as compared to other tissues (Figure 3.4D). PX/Br-
C16-PX from 48 hr to 96 hr was between 0.29 and 0.45 in dissected lung tumors, and 
between 1.24 and 2.97 in pleural fluid containing pleural tumors, likely indicating favorable 
conversion of the conjugate to PX in these compartments. Considering that the tubulin 
stabilization activity and cytotoxicity of the conjugate was lower than PX at the same 
concentration (Figure 3.2), the greater conversion in tumor tissue enhances in vivo efficacy 
of the NPs. The significant conversion in pleural fluid may provide a better chance for the 
converted PX to diffuse into adjacent tumor sites in the lung, and enable a therapeutic benefit 
against pleural tumors. On the other hand, minimal conversion in non-tumor tissues and 
organs could help to shield healthy tissues from systemic toxicity.  
 
4.6 In vivo toxicity of Br-C16-PX NPs  
In vivo toxicity of the Br-C16-PX NPs was investigated with a single i.v. dose at 75 
mg/kg in non-tumor-bearing nude mice. Liver and kidney functions were evaluated with 
levels of blood urea nitrogen (BUN), alanine aminotransferase (ALT), alkaline phosphatase 
(ALP) and albumin. Urea is produced in the liver and eliminated by the kidney, thus lower 
BUN level may indicate liver disease and greater level may be related to kidney dysfunction. 
ALT and ALP are both produced mainly by the liver thus increased levels in the blood are 
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mostly caused by liver damage. Abnormal albumin level may be attributed to liver or kidney 
diseases. At 4 hr, 24 hr, and 48 hr after intravenous administration of Br-C16-PX NPs at a 
very high dose of 75 mg/kg, no statistical difference was observed for the levels of BUN, 
ALT, ALP and albumin as compared to the control group, suggesting no NP-associated liver 
or kidney toxicity (Table 3.3).   
 
5. Discussion  
Due to the difficulty in directly incorporating PX into a safe and effective 
formulation, PX conjugates or derivatives have been developed either to enhance water 
solubility thus decrease the amount of toxic co-solvents or to increase its lipophilicity and 
stability in hydrophobic carrier systems. Previously Ali et al. synthesized a series of 
lipophilic paclitaxel conjugates bearing six, eight, 12, 14, or 16-carbon 2-bromoacyl chains at 
the 2’-position [30]. When evaluated in human breast carcinoma cell line MCF-7, the 
bromoacyl PX conjugates were 50- to 250-fold more cytotoxic than their counterparts 
without bromine, indicating Br-induced hydrolysis. PX conjugate with a long 16-carbon 
chain exhibited decreased cytotoxicity as compared to conjugates with shorter chain lengths, 
but was therapeutically more efficacious when loaded into liposomes for the treatment of 
mice ovarian cancer. However, the liposomal formulation had a relatively low molar ratio of 
bromoacyl taxane and a wide size range between 90 nm and 140 nm. Furthermore, the in 
vivo behavior of the system was not further investigated except for survival analysis.  
In current studies, 2’-(2-bromohexadecanoyl)-paclitaxel (Br-C16-PX) was 
synthesized and incorporated into lipid-based NPs for the treatment of NSCLC. The 
conjugate was evaluated for tubulin stabilization activity and cytotoxicity. In the tubulin 
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polymerization assay (Figure 3.2), Br-C16-PX exhibited a dose-dependent tubulin 
stabilization effect. This indicated that the tubulin polymerization activity of Br-C16-PX was 
compromised to some extent presumably due to the modification of the 2’-OH group, which 
has been recognized to be critical for the microtubule binding and cytotoxic effect of PX [6, 
7, 31]. However, when the Br-C16-PX was increased from 10 µM to 34 µM, accelerated 
microtubule polymerization was observed similar to PX at 10 µM, indicating a tubulin 
stabilization effect of the conjugate. 
Similar to compromised tubulin polymerization activity, free Br-C16-PX is expected 
to be less cytotoxic than the parent drug PX due to the conjugation of the 2’ hydroxyl group 
[6]. Due to increased lipophilicity of Br-C16-PX after conjugation of the 16-carbon chain, its 
solubility in DMSO was not high enough to enable analysis of the IC50 for free Br-C16-PX 
via MTT assay. Cytotoxicity of the Br-C16-PX NPs was investigated instead and results 
showed an IC50 62.2-fold greater than free PX, which is consistent with other reported 2’-PX 
conjugates [6, 7, 30, 31].   
The lipid-based NPs with Br-C16-PX were optimized to have a drug loading as high 
as 40% (w/w, drug/oil) and a drug entrapment of 66.45 ± 0.02%. Previously, our laboratory 
developed PX NPs to passively target PX to tumors and to overcome Pgp-mediated drug 
resistance [151]. However, the loading capacity was only 7.5% by weight and PX was shown 
to be rapidly released in vivo presumably due to inadequate affinity of PX to the Miglyol oil 
core of the NP formulation. Later, a C22-PX conjugate was synthesized to enhance 
lipophilicity of the drug [138]. Although the C22-PX NPs exhibited therapeutic efficacy and 
improved pharmacokinetic profile in a 4T1 breast cancer model, the drug loading was only 
7.7% by weight and the conversion of C22-PX to PX was unsatisfactory (only 5-7% after 48 
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hr  incubation in 4T1 tumor homogenate at 37°C). In the optimized formulation of Br-C16-
PX NPs, the enhanced drug loading and drug entrapment are attributable to increased 
lipophilicity through addition of the 16-carbon chain and decreased amount of surfactants in 
the NP formulation. From Formulation I to Formulation IV (Table 3.1), Brij 78 
concentration was decreased from 3.7 mg/ml to 2.0 mg/ml and TPGS concentration was 
decreased from 1.2 mg/ml to 1.0 mg/ml. Although a monodisperse population (200 nm) with 
low polydispersity index (around 0.2) was observed for all formulations by dynamic light 
scattering, an additional population of smaller particle size (~30 nm) was identified in GPC 
elution profile mainly for Formulation I and Formulation II. These Br-C16-PX-containing 
smaller particles eluted in fractions 6 to 9, and are likely to be micelles generated due to 
excess amount of surfactants. With decreasing concentrations of the surfactants, decreasing 
amount of Br-C16-PX was observed in fractions 6-9 of the GPC elution profile, leading to 
greater drug entrapment in the 200 nm oil-filled NPs (fractions 3 to 5) in Formulation III and 
Formulation IV.  
 The optimized Br-C16-PX NPs (Formulation IV) were evaluated for the treatment of 
NSCLC. About 15% of lung cancer cases are diagnosed at early stage with a five-year 
survival of 52.6%. For patients with distant tumors at the time of diagnosis, the five-year 
survival rate is only 3.5% [119]. More efficacious therapy options for advanced lung cancer 
are in great demand. However, treatments are started relatively early in the majority of 
preclinical studies in orthotopic lung cancer mouse model. Bao et al. treated orthotopic A549 
tumor with a heat shock protein 90 inhibitor starting on day 4 after tumor implantation, 
which is 10.5% of the 38-day median survival in control group [158]. Jin et al. started the 
treatment of orthotopic H460 tumor on day 10, which is 23.5% of the 42.5-day median 
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survival [159]. Furthermore, treatment of advanced lung tumor is more challenging due to 
well-developed and likely more aggressive primary tumor as well as potential metastasis. 
Doki et al. treated orthotopic Lewis Lung carcinoma with cisplatin either starting on day 1 or 
day 10, which is 4.8% and 47.6% of the 21-day median survival, respectively [160]. 
However, cisplatin suppressed primary lung tumor growth and lymph node metastasis only in 
the day 1 treatment group, and failed to show any significant therapeutic effect in the day 10 
treatment group.  
In our in vivo efficacy studies in the orthotopic NSCLC mouse model, the Br-C16-PX 
NP treatment was started on day 16 post tumor cell implantation (51.5% of the 31-day 
median survival) instead of day 5 in previous studies with Br-C16-DX NPs [157] to mimic 
the therapy of advanced NSCLC. The MTD of the Br-C16-PX NPs in non-tumor-bearing 
mice was determined to be between 90 mg/kg and 120 mg/kg of the conjugate. However the 
chemotherapeutic tolerance of orthotopic lung tumor-bearing mice is decreased due to 
compromised lung function and is related to the extent of tumor progress. In previous studies 
with Br-C16-DX NPs, the MTD for day 5 treatment in the orthotopic NSCLC model was 
80% of the MTD in subcutaneous model. For day 23 treatment in the orthotopic model, 64% 
of the subcutaneous MTD was still toxic and led to severe weight loss of the treated mice 
(unpublished data). Therefore, the drug dose in current studies was decreased proportionately 
based on the MTD in healthy mice. Two doses (60 mg/kg and 75 mg/kg) of the Br-C16-PX 
NPs were chosen and evaluated for in vivo efficacy. The median survival was slightly 
improved by the Br-C16-PX NPs at the lower dose and further improved at the high dose (p 
= 0.03) as compared to Taxol standard of care (Figure 3.3). After the treatment was started 
84 
in the NP 75 group, a minor weight loss was observed from which the mice recovered soon, 
so it is believed that 75 mg/kg is very close to the actual MTD in the tumor-bearing mice.   
There are several possible reasons for the superior therapeutic efficacy of the Br-C16-
PX NPs over Taxol. First of all, the MTD of the NPs was greatly increased (4-fold greater 
than Taxol) likely due to the fact that the NP formulation consists of generally regarded as 
safe (GRAS) excipients instead of toxic Cremophor and ethanol in Taxol, allowing for 
greater delivered dose. Moreover, the decreased clearance and prolonged circulation 
provided more time for the NPs to circulate and accumulate into the orthotopic tumors via 
the EPR effect. Indeed, in the pharmacokinetic studies (Figure 3.4 and Table 3.2), the 
plasma T1/2 of Br-C16-PX from NPs was increased to 7.9 hr as compared to PX from Taxol 
at 0.8 hr. AUC0-96hr of Br-C16-PX in plasma and tumor-bearing lung was 91.6-fold and 49.6-
fold greater than Taxol, respectively. In tumor-bearing lungs, the MRT of converted PX 
(32.2 hr) was 2.2-fold longer than Taxol (14.7 hr). The AUC0-96hr and AUC48-96hr of converted 
PX from the NPs were 1.1-fold and 2.7-fold greater than Taxol, respectively.  
In addition to increased drug exposure, the increased ratio of (converted PX/Br-C16-
PX) was observed primarily in tumor (ratio up to 0.45) and pleural fluid (ratio up to 2.97). 
The increased ratio likely indicated favorable conversion of the conjugate to PX in these 
compartments which would enable more effective tumor treatment. The improved conversion 
is attributable to the electron-withdrawing Br atom at the 2-position of the 16-carbon chain. 
The selective conversion in pleural fluid and tumor is likely caused by tissue-specific 
enzymatic activity and/or pH environment. Shaffer et al. found that the metabolism of a 
paclitaxel poliglumex is at least partially mediated by the lysosomal enzyme cathepsin B, 
whose expression is up-regulated in many tumor types including lung tumor [88]. 
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Additionally, lower pH in tumor interstitial fluid and also late endosomes and lysosomes 
could facilitate chemical hydrolysis of the Br-C16-PX conjugate especially with the presence 
of bromine. The pH of tumor interstitial fluid has been found to be slightly lower than that of 
normal tissue. Human tumors were observed to have a wide pH range between 5.85 and 7.68 
but generally within 6.2 to 6.9 [161, 162]. Moreover, previous studies showed that 
endocytosis pathway is likely to be involved in the cellular uptake of BTM NPs [151]. Once 
the Br-C16-PX NPs were internalized into tumor cells, the acidic condition in late endosomes 
and lysosomes could further accelerate hydrolysis to release PX. Pleural effusion generated 
in the orthotopic mouse model was thick fluid containing tumor cells, red blood cells, and 
some immune cells. The increased ratio in pleural fluid than lung tumors may be caused by 
sequestration of the NPs in pleural cavity, and the absence of tumor stroma in the fluid 
environment thus easier access of the NPs to pleural tumors as compared to solid lung 
tumors.  
We have developed Br-C16-PX NPs with demonstrated improved PK and antitumor 
efficacy as compared to Taxol. CD44 targeted NPs are under investigation to increase tumor 
cell uptake thus further enhance the therapeutic index of the developed system [156].  
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Figure 3.1 Synthesis scheme of Br-C16-PX 
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Figure 3.2 Toxicity study of Br-C16-PX. (A) Tubulin polymerization activity and Vmax 
comparison (*, p < 0.05; **, p < 0.01). (B) Cytotoxicity study of Br-C16-PX NPs, blank NPs 
and free PX in A549-luc-c8 cells after 48 hr incubation. The IC50 of blank NPs was 
calculated at the drug equivalent dose.  
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Figure 3.3 In vivo efficacy study in an orthotopic NSCLC model. Mice were implanted with 
5 million A549-luc-c8 cells in the left lung parenchyma on day 0. Starting on day 16, Taxol 
or Br-C16-PX NPs were given as weekly i.v. injections for 6 weeks (indicated by the arrows 
in Figure 3A). (A) Survival curve. Survival was significantly improved by Br-C16-PX NPs at 
75 mg/kg as compared to Taxol at 19 mg/kg (p = 0.03). (B) and (C), in vivo bioluminescence 
imaging (color scale blue 3.65E6, red 6.68E7), gross lung images, and histology (scale bar, 3 
mm) of the surviving mice in NP 60 mg/kg group (B) and NP 75 mg/kg group (C) 154 days 
post tumor implantation. Tumor nodules are indicated by the arrows.  
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Figure 3.4 Pharmacokinetic (PK) and biodistribution studies in an orthotopic NSCLC model 
(3 mice per time point). (A) and (B), PK profile of Br-C16-PX NPs and Taxol in plasma (A) 
and tumor-bearing lungs (B). Drug concentrations of PX from Taxol (open circle), Br-C16-
PX from NPs (triangle) and PX converted from Br-C16-PX NPs (square) were quantified by 
LC-MS/MS. (C) Biodistribution of Br-C16-PX in liver, spleen, lung, kidney, and pleural 
fluid at predetermined time points. (D) Ratio of converted PX to Br-C16-PX in different 
tissues. Ratio = (molar concentration of PX converted from Br-C16-PX) / (molar 
concentration of Br-C16-PX). 
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Table 3.1 Formulation optimization and characterization of Br-C16-PX loaded BTM NPs. 
Formulation IV was the optimal Br-C16-PX NPs and was evaluated in subsequent in vitro 
and in vivo studies.  
 
Formulation Br-C16-PX (mg/ml) 
Miglyol 
(mg/ml) 
Brij 78 
(mg/ml) 
TPGS 
(mg/ml) 
Particle Size 
(nm) 
% Drug  
in F3-5 
I 0.5 2.5 3.7 1.2 184 ±  7 50.87 ± 0.01 
II 0.5 2.5 2 1.6 188 ±  3 60.64 ± 0.05 
III 0.5 2.5 2 1 170 ±  9 70.00 ± 0.06 
IV 1 2.5 2 1 202 ± 3 66.45 ± 0.02 
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Table 3.2 Summary of important pharmacokinetic parameters of PX from Taxol, converted 
PX and Br-C16-PX from Br-C16-PX NPs. These parameters were calculated from the data in 
Figure 4 by non-compartmental analysis.  
 
Specimen Parameter Unit PX (Taxol) 
Br-C16-PX NPs 
Br-C16-PX PX (converted) 
Plasma 
AUC0-96hr ng/ml·hr 16,681.10 1,530,414.10 2,982.70 
AUC48-96hr ng/ml·hr N/A 24,249.10 1,545.40 
T1/2 hr 0.8 7.9 27.2 
MRT hr 0.7 2.2 14.5 
CL ml/hr/kg 1,136.90 48.9 23,932.90 
Vd ml/kg 1,375.70 557.7 939,305.10 
Lung 
AUC0-96hr ng/ml·hr 52,478.50 2,601,702.80 57,451.00 
AUC48-96hr ng/ml·hr 8,825.40 1,508,174.00 23,852.00 
T1/2 hr 30.3 80.9 34.4 
MRT hr 14.7 42.8 32.2 
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Table 3.3 Summary of NP toxicity study. Levels of blood urea nitrogen (BUN), alanine 
aminotransferase (ALT), alkaline phosphatase (ALP) and albumin were measured at 4 hr, 24 
hr, and 48 hr after i.v. administration of the Br-C16-PX NPs at 75 mg/kg. No statistical 
difference was observed among all groups.  
 
Biochemical 
parameters Saline 
Br-C16-PX NPs (75 mg/kg) Statistical 
difference 4 hr 24 hr 48 hr 
BUN (mg/dl) 23.8 ± 5.6 20 ± 2.8 24.0 ± 1.4 25.5 ± 0.1 No 
ALT (U/L) 22.5 ± 8.8 37 ± 5.7 32.0 ± 9.9 29 ± 12.7 No 
ALP (U/L) 73.3 ± 19.2 79.5 ± 9.2 80.5 ± 4.9 72.5 ± 7.8 No 
Albumin (g/dl) 2.8 ± 0.4 3.0 ± 0.1 2.9 ± 0.6 2.8 ± 0.3 No 
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CHAPTER 4.  
SUMMARY AND FUTURE DIRECTIONS 
 
1. Summary 
Paclitaxel (PX) is widely used as a chemotherapeutic drug to treat multiple types of 
cancer including lung, ovarian, prostate and breast cancer. There are currently two 
commercial products of PX, Taxol and Abraxane. However, Taxol causes severe side effects 
such as anaphylaxis and hypersensitivity due to the toxic co-solvents Cremophor EL and 
dehydrated ethanol [2]. Abraxane eliminated the use of Cremohpor by delivering PX via 
albumin and therefore exhibits decreased toxicity. However, to date, the survival and 
pharmacokinetic benefits of Abraxane are not statistically significant in clinical studies [4, 5]. 
The overall goal of this research was to develop a formulation to safely and effectively 
deliver PX for the treatment of non-small cell lung cancer (NSCLC). Significantly improved 
therapeutic index and pharmacokinetic profile were achieved by formulating the PX 
conjugate Br-C16-PX in the lipid-based BTM NPs.  
 A clinically-relevant animal model is needed for in vivo evaluation of the developed 
formulation. There was a significant effort to establish a new orthotopic NSCLC model in 
this project as it would be far more clinically relevant as compared to a more conventional 
subcutaneous model. Chapter II described the development of the orthotopic mouse model 
and evaluation of Br-C16-DX NPs. The model was established through dorsal side injection 
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of luciferase-expressing A549 cells which provided 94% lung tumor development rate. 
Further characterizations including survival study, histology staining, bioluminescence 
imaging (BLI) and micro PET/CT imaging were performed. Importantly, the strong linear 
correlation (R2 = 0.86) between quantified in vivo BLI and PET signal supported the use of 
BLI for tumor growth monitoring. The therapeutic efficacy of Br-C16-DX NPs versus 
Taxotere was investigated in this model. The results demonstrated longer progression-free 
survival (~ 70 days to 105 days) and median survival (131 days to 158 days) of the NP-
treated group as compared to the Taxotere group.  
 In Chapter III, the development and evaluation of Br-C16-PX NPs for NSCLC 
treatment were described. Due to the limited solubility of PX in the Miglyol oil core, a more 
lipophilic PX conjugate Br-16-PX was synthesized and formulated into BTM NPs for 
improved drug entrapment and drug retention. An electron-withdrawing Br atom was 
included in the fatty acid chain to facilitate the release of more active parent drug PX. The 
Br-C16-PX NPs were optimized by decreasing the amount of surfactants and increasing drug 
concentration, leading to a drug entrapment as high as 66% at 1 mg/ml Br-C16-PX. The NPs 
were evaluated in the luciferase-expressing A549 cells in vitro and in the developed 
orthotopic NSCLC mouse model. The results demonstrated that the Br-C16-PX NPs had 
greater maximum tolerated dose (75 mg/kg versus 19 mg/kg) and improved pharmacokinetic 
profile as compared to Taxol, which resulted in significantly prolonged median survival (88 
days versus 70 days) for the treatment of advanced NSCLC.  
 In conclusion, the developed BTM NPs with Br-C16-PX may serve as safer and more 
efficacious treatment options for NSCLC. The established orthotopic NSCLC mouse model 
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represents a feasible, reproducible, and clinically-relevant experimental mouse model to test 
current and potential therapies including nanomedicines.  
 
2. Future directions 
The Br-C16-PX NPs developed in the present studies have been proven to have 
prolonged circulation and superior therapeutic index as compared to Taxol. Importantly, the 
incorporation of Br-C16-PX in the nanocarrier has the potential to bypass Pgp-mediated drug 
efflux in resistant tumor. Therefore, the current formulation could be further investigated for 
the treatment of resistant NSCLC. In vitro cytotoxicity study in Pgp-overexpressing A549 
cells is proposed to test whether the Br-C16-PX NPs exhibit a lower IC50 compared to free 
Br-C16-PX or PX. In vivo efficacy study is suggested if a higher cytotoxicity is observed for 
the Br-C16-PX NPs in vitro.  
Moreover, the Br-C16-PX NPs could be further optimized to improve the therapeutic 
efficacy. The NPs were only passively targeted to tumors via EPR effect in current studies. 
The next step would be incorporating a targeting ligand into the formulation to actively target 
cancer cells and enhance cellular uptake. Secondly, high liver and spleen uptake was 
observed in pharmacokinetic studies despite prolonged circulating time and significantly 
increased AUC. Denser pegylation to better shield the vehicle from RES would significantly 
increase the dose that could reach tumor tissue. Finally, since the tubulin polymerization 
activity of the conjugate was compromised due to the conjugation at 2’-OH, more efficient 
conversion of Br-C16-PX to the parent drug PX would further enable improved antitumor 
effect.  Fluorescent labeling of the BTM NPs will be discussed to achieve convenient 
characterization in subsequent studies.   
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2.1 Fluorescent labeling of the BTM NPs 
Fluorescent labeling of the drug delivery vehicle is an important approach to track NP 
localizations both in vitro and in vivo. Previously various dyes including BODIPY FL C12, 
Nile Red and 5-FAM-cadaverine (Figure 4.1) have been investigated either to be directly 
incorporated in BTM NPs (BODIPY and Nile Red) or to be conjugated with Brij 700 and 
then incorporated (5-FAM-cadaverine). However, none of them were successfully 
formulated in the NPs either due to limited solubility or insufficient affinity to the Miglyol 
oil core as evidenced by gel permeation chromatography (GPC). Therefore, a highly 
lipophilic dye with great affinity to Miglyol is needed for fluorescent labeling of the BTM 
NPs.   
 Andrey et al. reported highly lipophilic fluorescence derivatives of 3-alkoxyfavone 
(F888) and Nile Red (NR668) which could be encapsulated in 40 nm lipid nano-emulsions 
(Figure 4.2) [163]. F888 and NR668 were stably incorporated in the lipophilic core of the 
nano-emulsion at exceptionally high concentrations of 170 mM and 18 mM, respectively, 
yielding bright non-leaking nano-droplets. In vitro release studies in serum-containing 
medium showed minimum release of the synthesized dye from the F888-NR668 nano-
droplets even after 6 hr of incubation, while immediate release of Nile Red from the nano-
droplets was observed. Furthermore, in vivo imaging studies in zebrafish demonstrated that 
there was no leaking of NR668 upon injection in the sinus venosus and subsequent 
distribution to the whole vasculature of zebrafish embryos. Figure 4.3 showed the 
localization of Nile Red in the endothelium and the global diffuse labeling of the entire 
embryo (C), and no co-localization of NR688 with the endothelial cells (F).  
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 Importantly, the Labrafac CC oil core utilized in the nano-droplets is very similar to 
the Miglyol oil core of the BTM NPs. They are both caprylic/capric triglyceride used as 
emollient to improve spreadability of cosmetics. Therefore, it is proposed that the highly 
lipophilic dye F888 or NR668 has the potential to be encapsulated in BTM NPs with minimal 
leaking both in vitro and in vivo. F888 is viscous oil readily miscible in Labrafac CC and 
NR688 is solid with lower solubility. The dye entrapment in BTM NPs could be evaluated 
using GPC analysis with PBS elution. The dye concentration and fluorescence properties of 
the NPs need to be closely monitored. It was reported that NR668 at 90 mM could be self-
quenched (% quantum yield of 13%) as compared to 18 mM (% quantum yield of 60%). 
F888, on the other hand, did not have this concern with a % quantum yield of 72% and 87% 
at 170 mM or 17 mM, respectively. Successful fluorescent labeling of BTM NPs would 
enable investigations of intracellular trafficking and tissue distribution through fluorescent 
quantification methods such as flow cytometry or confocal microscopy. 
 
 
2.2 Targeted delivery to NSCLC  
CD44 and EGFR (epidermal growth factor receptor) have been investigated as 
potential targets for tumor-specific delivery to NSCLC. In vitro screening with three different 
NSCLC cell lines A549, H460 and H23 demonstrated greater expression levels of CD44 as 
compared to EGFR, especially in A549 cells (Figure 4.4). Therefore, CD44 was selected as 
the NSCLC target and investigated in Mumper lab by Dr. S. Rahima Benhabbour.  
 CD44 is a glycoprotein present on cell surface involved in cell–cell interactions, cell 
adhesion and migration, and plays an important role in tumor invasion and metastasis [164]. 
It is a natural ligand for hyaluronic acid and also interacts with other proteins in extracellular 
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matrix such as collagen and MMP (matrix metalloproteinases). Previously, our laboratory 
attached CD44 mAb to BTM NPs via the affinity binding between his-tagged mAb and 
Brij78-NTA-Ni (Figure 4.5A). In vitro cell uptake studies in A549 cells showed a dose-
dependent uptake with up to 90% internalization of the CD44-targeted Ni-NPs, as compared 
to significantly lower (<10%) uptake for the untargeted Ni-NPs. Both Flow cytometry results 
quantifying FITC fluorescence from the CD44 mAb (Figure 4.5B) and ICP-MS analyses 
quantifying Ni (Figure 4.5C) demonstrated a dose-dependent internalization of the targeted 
NPs. Furthermore, the internalization could be competed off by adding free CD44 mAb prior 
to incubation with the NPs, indicating CD44-mediated cell uptake of the targeted NPs (data 
not shown).  
 For in vivo administration, stronger covalent binding instead of affinity binding is 
preferred. Therefore, Brij 78-acid (Figure 4.6A) was synthesized to covalently conjugate 
CD44 mAb by forming a stable amide bond between the carboxyl group of Brij 78-acid and 
the primary amine of the mAb post NP formation (Figure 4.6B). In vitro uptake study in 
A549 cells demonstrated a dose-dependent cell uptake of the targeted NPs and a significantly 
lower uptake of the untargeted NPs (Figure 4.6C). Importantly, incorporation of CD44 in 
targeted NPs were previously characterized only with size measurement and fluorescence 
reading of each fractions following GPC, which demonstrated greater than 90% association 
of CD44 with the NPs. Light scattering intensity measurement of all GPC fractions 
accompanied with fluorescence reading is suggested to further validate the data. Efficacy 
studies in the orthotopic NSCLC mouse model remains to be performed to evaluate the in 
vivo performance of the targeted system.  
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 The fluorescence labeling of BTM NPs proposed in Section 2.1 will enable Flow 
cytometry analysis for cellular uptake of the NPs. Although previously Ni quantification was 
utilized to monitor cell uptake, a small portion of the Brij 78-NTA-Ni might dissociate from 
the NPs and get internalized in its free form. The lipophilic dye F888 or NR668 will be 
dissolved in the Miglyol oil core and is expected to have minimal leaking from the NPs both 
in vitro and in vivo. Tumor cell uptake of the targeted NPs in the orthotopic NSCLC model 
could be evaluated by confocal microscopy and compared to untargeted NPs. Considering 
that the total tumor uptake may not necessarily increase in PK/biodistribution study, the 
fluorescence quantification at cellular level plays an important role to elucidate the in vivo 
advantage of the targeting ligand. However, it should be noted that whole organ fluorescence 
imaging needs to be utilized and interpreted with care. As reported by Liu et al., fluorescence 
signals of Texas-Red or Cy5.5 in both liver and spleen were significantly attenuated as 
compared with those in the tumor due to the intrinsic tissue absorption and scattering 
[165]. Quantification of drug concentrations or radiolabeled NPs could provide more reliable 
information on tissue distribution.  
 
2.3 Pegylation  
Extensive protein binding occurs immediately once NPs are exposed to biological 
medium [166, 167]. Approximately fifty different plasma proteins have been found to bind to 
the surface of NPs, including opsonins and dysopsonins [168]. Opsonin binding by 
fibrinogen or complement factors is believed to facilitate clearance of the NPs from the 
circulation via macrophage recognition and phagocytosis, while dysopsonin binding by 
albumin helps to prolong systemic circulation of the NPs [169]. Pegylation has been 
100 
extensively investigated to minimize opsonization of the NPs and to decrease RES uptake. 
Intense presentation of PEG on NP surface forms a well-hydrated barrier layer which 
sterically repels protein binding from both opsonins and dysopsonins.  
 Brij 700, a polyethoxylated stearyl ether with 100 repeating units of ethylene oxide 
(molecular weight ~ 4,670), was formulated in BTM NPs for the purpose of pegylation. 
Although the BTM NPs in animal studies were pegylated with 8% Brij 700 (weight % to the 
oil phase), the amount of Brij 700 that stays with the NPs in vivo and the degree of 
pegylation were unknown. As observed from PK/biodistribution studies of Br-C16-PX NPs 
(Figure 3.4), Br-C16-PX was detected primarily in plasma within the first 4 hr and mainly in 
liver and spleen afterwards. Similar biodistribution profiles were observed previously with 
Br-C16-DX BTM NPs and C22-PX BTM NPs [135, 138]. The liver and spleen uptake is 
probably due to insufficient PEG coating and its “mushroom” conformation on NP surface. 
As described by Flory and De Gennes, surface-grafted PEG adopts two different statistical 
configurations: “mushroom” and “brush,” which are dictated by the relationship between the 
distance of two grafting sites (D) and the radius of the random coil in solution (Rf) [170-172]. 
PEG at a lower density (D > Rf, Figure 4.7A) is presented as “mushroom” configuration 
which leaves gaps between the “mushroom” for protein binding, while PEG at a greater 
density (D < Rf, Figure 4.7B) leads to less mobility of the extended PEG chains and 
subsequent transition to a “brush” configuration which provides good protection [173-175]. 
Therefore, denser pegylation of BTM NPs at the “brush” conformation is needed to decrease 
liver and spleen uptake and prolong systemic circulation.  
 Since Brij 78 is a very important component of BTM NPs, synthesis of Brij78-PEG is 
proposed to improve pegylation of the NPs. Brij78-acid (Figure 4.6A) could be conjugated 
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with functionalized PEG-amine that is commercially available. The PEG chain needs to have 
a minimum molecular weight of 2000 in order to achieve RES-avoidance characteristics 
[173, 176, 177]. Heterobifunctional FITC-PEG-NH2 is proposed to enable convenient 
conjugation and characterization of the pegylated NPs. The primary amine will be conjugated 
with Brij78-acid, while the FITC fluorescence allows for quantification of Brij78-PEG 
incorporation in the BTM NPs via GPC (Sepharose CL4B) followed by fluorescence reading 
and light scattering intensity reading of each fraction. In vivo PK studies are proposed to 
further evaluate the effect of pegylation and decreased liver and spleen uptake is expected. 
Notably, the amount of Brij78-PEG included in the formulation needs to be modulated not 
only for protection of the NPs from opsonization, but also for effective targeting to tumor 
cells. The CD44 mAb may need to be attached to Brij78-PEG instead of Brij78-COOH to 
ensure its accessibility for CD44 recognition.  
 
2.4 Conversion of Br-C16-PX to PX  
Conjugation of a fatty acid chain to the 2’-OH of PX leads to compromised 
microtubule stabilization activity and cytotoxicity. As shown in Chapter III, Br-C16-PX at 10 
µM had significantly lower Vmax as compared to free PX at the same concentration, and the 
IC50 of Br-C16-PX NPs in A549-luc-c8 cells was significantly greater as compared to PX 
(Figure 3.2). Therefore, efficient conversion of Br-C16-PX to the parent drug is crucial for 
its antitumor activity. However, limited converted drug was observed in PK/biodistribution 
studies (Figure 3.4) with an apparent maximum conversion of ~70% in pleural fluid and 
~30% in tumor, respectively. The pleural fluid- and tumor- specific conversion is quite 
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encouraging yet more efficient release of PX from the conjugate will greatly improve the 
therapeutic index of the Br-C16-PX NPs.  
 The “apparent” conversion of Br-C16-PX to PX are the overall representations of 
several correlated factors including tissue distribution and cellular uptake of the NPs, release 
of the conjugate from the NPs, conversion of the conjugate to PX after release, and 
metabolism of Br-C16-PX and the converted PX. There are several possible reasons for 
limited apparent conversion. As discussed in Section 2.2, the cell uptake of the untargeted 
NPs was below 10% as observed in A549 cells. Targeted NPs may enhance tumor cell uptake 
and make the Br-C16-PX accessible to tumor cell-specific enzymes thus facilitate the 
conversion to PX. Another possibility is that a majority of the Br-C16-PX NPs was trapped 
in intracellular compartments (like in endosomes after endocytosis) instead of being released 
to the cytosol where microtubule stabilization takes place, or Br-C16-PX remains with the 
NPs even in the cytosol which hinders tubulin binding. At last, the ester bond between the 
carbon-16 chain and PX may be too stable under the specific enzymatic and pH environment 
in the orthotopic NSCLC tumor. Approaches to improve Br-C16-PX release from the NPs 
after cell uptake and chemistry manipulation of the conjugate are discussed here.  
  
2.4.1 Endosomal escape and release of Br-C16-PX from BTM NPs 
To understand the release of Br-16-PX from the NPs after tumor cell uptake, the 
intracellular trafficking of BTM NPs needs to be elucidated. An in vitro cell uptake study in 
A549-luc-c8 of the fluorescently labeled NPs (discussed in Section 2.1) and confocal 
microscopy observation are proposed for this purpose. Endosome markers such as early 
endosome antigen 1 (EEA1, for early endosomes) and lysosomal-associated membrane 
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protein 1 (LAMP1, for late endosomes and lysosomes) could be used to monitor the co-
localization of the NPs with these intracellular compartments [178].  
 If NPs are trapped in endosomes or lysosomes, incorporation of an L-arginine lauryl 
ester is proposed to enable endosomal escape. L-arginine lauryl (AL, Figure 4.8A) contains a 
hydrophobic chain and is expected to be formulated into BTM NPs. Its hydrophilic head 
contains primary and secondary amines which could be protonated at acidic and neutral pH, 
respectively, leading to membranolytic capability. As reported by Li et al., AL-incorporated 
nanostructure lipid carriers exhibited increased hemolysis activity at pH 5.5 as compared to 
pH 6.5, with the lowest activity at pH 7.4, indicating pH-dependent membranolytic capability 
(Figure 4.8B) [179]. A pH-responsive fluorescent probe calcein was used for in vitro study 
in MCF-7 cells. Calcein undergoes self-quenching in acid environment and emerges green 
fluorescence only at neutral pH. Increasing green fluorescence was observed from 1 hr to 4 
hr after incubation, indicating lysosomal rupture and release of the AL-incorporated carriers 
(Figure 4.8B). Furthermore, improved in vivo antitumor activity was observed for AL-
incorporated carries as compared to lipid carrier without AL. Therefore, it is proposed that 
incorporation of AL in BTM NPs will facilitate endosomal/lysosomal escape of the NPs and 
improve the therapeutic efficacy.  
 If endosomal/lysosomal escape alone is not sufficient to enable release of Br-C16-PX 
from the NPs into the cytosol of tumor cells, a mechanism to destabilize the vehicle may be 
needed. In this case, incorporation of an artificially designed pH-sensitive fusogenic peptide 
GALA (WEAALAEALAEALAEHLAEALAEALEALAA) is proposed [180]. The GALA 
peptide was reported to have a random coil conformation around pH 7 due to charge 
repulsion between the negatively charged Glu residues. When the pH of the solution was 
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decreased to 5, the peptide formed α-helix structure due to the decrease in the level of 
repulsion by the non-ionized Glu [181, 182]. When presented on liposome surface, the 
increased hydrophobicity of the α-helix GALA in endosomes lead to translocation of the 
peptide on liposome membrane and fusion with endosome membrane, which enabled release 
of the incorporated cargo from the liposome as well as  endosome escape (Figure 4.9) [183]. 
BTM NPs are lipid NPs instead of liposomes with lipid bi-layer, thus the membrane fusion 
with endosome may not be applicable. However, it is proposed that the incorporation of 
GALA on the surface of BTM NPs could induce instability of the NPs followed by PX 
release due to the increased hydrophobicity of GALA at lower pH. Together with the 
endosomal escape approach described above, release of Br-C16-PX into the cytosol of tumor 
cells could be achieved.  
 Alternatively, pH-sensitive polymers could be used for endosomal escape as well as 
carrier rupture to release the free cargo [184]. However, this will require substantial 
modification and optimization of the formulation and is not discussed here. 
  
2.4.2 Chemistry modification of the PX conjugate  
In addition to the possibilities discussed above, the ester linkage between the carbon-
16 chain may be too stable under the specific enzymatic condition and pH environment in the 
orthotopic NSCLC tumor.  
 A diglycolic linker is proposed to sensitize the ester bond between the conjugated 
moiety and PX in order to improve cytotoxicity and in vivo efficacy. The IC50 of Br-C16-PX 
NPs in A549-luc-c8 cells was 62.2-fold greater than free PX (Figure 3.2B), while PX 
prodrug with a diglycolic linker between PX and the fatty acid chain (Figure 4.10) exhibited 
105 
an IC50 only 6.2-fold and 12.3-fold greater than PX in MCF7 and A2780 cells, respectively 
[27]. Moreover, the diglycolic-linked conjugates were shown to be more effective than the 
succinate-linked conjugates both in vitro and in vivo since the diglycolic linker is more 
readily cleavable. Another promising approach is cathepsin B-specific PX release. Cathepsin 
B-sensitive PX conjugates with improved therapeutic index have been reported including 
CT-2103 which is in clinical trial [56, 88]. Incorporation of a valine-citrulline linker as a 
cathepsin B substrate may enhance the conversion of the PX conjugate to the parent drug.  
However, the lipophilicity of the conjugate may be compromised due to the relatively 
hydrophilic dipeptide. 
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Figure 4.1 Structure of (A) BODIPY FL C12, (B) Nile Red and (C) 5-FAM-cadaverine 
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Figure 4.2 (A) F888, (B) NR668 and (C) schematic presentation of a nanodroplet [163] 
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Figure 4.3 Zebrafish microangiography using nano-droplets containing 0.1 wt % of Nile Red 
(A, B and C) or 1 wt % of NR668 (D, E and F) [163]. The images present the global view 
(upper panels) and a zoomed in view of the trunk vasculature (lower panels). The images in 
green (A and D) present endothelial cells expressing eGFP, while the images in red present 
fluorescence of Nile Red (B) and NR668 (E), 30 min after injection of the nano-emulsion. 
The arrows show the endothelial cells. The merged image (C and F) shows the co-
localization of Nile Red or NR688 with the endothelial cells. 
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Figure 4.4 Comparison of CD44 and EGFR expression levels in NSCLC cell lines. Data and 
figure generated by Dr. S. Rahima Benhabbour. Flow cytometry performed by Dr. Chris 
Luft. 
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Figure 4.5 (A) Brij78-NTA-Ni. (B) and (C), NP internalization in A549 cells measured by 
FITC fluorescence on CD44 (B) or Ni on Brij78-NTA-Ni (C). Data and figure generated by 
Dr. S. Rahima Benhabbour. Flow cytometry performed by Dr. Chris Luft. 
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Figure 4.6 (A) Synthesis of Brij 78-acid (B) Preparation of CD44-targeted BTM NPs (C) 
Cell uptake study in A549 cells of targeted and untargeted NPs. Data and figure generated by 
Dr. S. Rahima Benhabbour. Flow cytometry performed by Dr. Chris Luft. 
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Figure 4.7 Schematic illustrations of PEG configurations on NP surface [173, 174]. (A) 
“Mushroom” configuration in which the low surface coverage of PEG chains leaves gaps on 
NP surface for opsonization. (B) “Brush” configuration in which the high surface coverage 
leads to lack of mobility of the extended PEG chains for good protection. 
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Figure 4.8 L-arginine lauryl 
Hemolytic activity of BSA-NLCs and BSA
(C) Confocal images of MCF
AL-incorporated nanostructure lipid carriers. Lysosomes
and nanostructure lipid carriers were labeled with calcein which emerges green fluorescence 
only at neural pH but not at acidic pH. 
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ester [179]. (A) Structure of L-arginine lauryl ester (AL) 
-AL-NLCs in PBS of pH 5.4, pH 6.5 and
-7 at 1 hr (left), 2 hr (middle) and 4 hr (right) incubat
 were stained with lyso
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Figure 4.9 GALA-mediated membrane fusion and endosomal escape [183]. MEND, 
multifunctional envelope-type nanodevice.  
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Figure 4.10 PX prodrug with a diglycolic linker 
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APPENDIX 
 
STANDARD OPERATING PROCEDURE 
Cell Culture and Preparation for the Orthotopic NSCLC Model 
 
Animal model:  Orthotopic NSCLC model in nude mice established by the Mumper lab in 
Project 3 of the CCNE 
Cell line:  A549-luc-C8 Bioware®, Caliper Life Sciences, Catalog # 119266 
 Cells should be used between passages 1-20.  Do not use after 20 
passages.  
Reagents:  Matrigel, BD Biosciences, Catalog # 356234 
       Geneticin® 50 mg/ml, GIBCO, Catalog # 10131-035 
       DPBS (1X), GIBCO, Catalog # 14190-144 
RPMI Medium 1640 (1X), GIBCO, Catalog # 11875-093 
FBS, GIBCO, Catalog # 26140-079 
Pen Strep, GIBCO, Catalog # 15140-122 
0.05% Trypsin-EDTA (1x), GIBCO, Catalog # 25300-054 
Supplies:       2.0 ml Cryogenic Vial, Corning Incorporated, Catalog # 430488  
        1.5 ml Microcentrifuge Tube, sterilized, Fisher, Catalog # 02-681-5 
        50 ml Centrifuge Tube, sterile, Corning Incorporated, Catalog # 430828 
        15 ml Centrifuge Tube, sterile, Corning Incorporated, Catalog # 430791 
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IEC CL40R Centrifuge, Thermo Electron Corporation, Catalog # 
11210927 
        1°C Freezing Container, NALGENE® Cryo, Catalog # 5100-0001 
 
5.1 Cell culture and storage of A549-luc-C8 cells  
1. Complete RMPI 1640 cell culture medium is prepared by supplementing RPMI 1640 
with 10% FBS and 100 µg/ml penicillin/streptomycin.  
2. G418-containing cell culture medium is prepared by adding geneticin (G418) to complete 
RPMI 1640 medium to a final concentration of 200 µg/ml. Please note that the addition 
of G418 is not required according to Caliper Life Sciences. We add it to ensure luciferase 
expression because it was observed that luciferase level of a different luciferase-
expressing A549 cell line obtained from University of Texas Southwestern was not 
stable.  
3. A549-luc-C8 cells are recovered from frozen vials stored under liquid nitrogen tank and 
cultured in complete RMPI 1640 without G418. Cells are cultured in an incubator with 
5% CO2 at 37°C.  
4. After 2 to 3 days, depending on cell growth, complete RPMI 1640 cell culture medium 
without G418 is changed to complete RPMI 1640 medium with G418 (200 µg/ml).  
5. Cell passage is performed as necessary. However, cells should not be used after passage 
number 20.   
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6. Multiple vials are slowly frozen at -80°C and then stored under liquid nitrogen. Cells to 
be frozen are suspended in complete RPMI1640 medium + 10% DMSO, and then slowly 
frozen overnight in Freezing Container at -80°C, and stored under liquid nitrogen.  
 
5.2 Cell culture of A549-luc-C8 cells for animal studies  
Important: All matrigel-related handling needs to be performed on ice.  
7.  Cell culture needs to be planned according to tumor implantation date and the number of 
cells needed. Usually less than two weeks of cell culture is preferred to ensure luciferase 
expression level.  
Example:  For a planned 40 mouse experiment:  To inject 5 million cells per mouse, 200 
million cells are needed for tumor implantation. However, plan for 1.5 to 2-fold more 
cells or 300-400 million cells (see step 12 for additional details). 
8.  A frozen vial of A549-luc-C8 cells is recovered and cultured in complete RPMI 1640 
without G418.  
9.  On the tumor implantation day, matrigel is slowly thawed on ice. Cells are detached from 
cell culture flasks by trypsin and harvested into a 50 ml centrifuge tube. 
10. After centrifugation at 4C 100 g for 5 min, trypsin is removed and cells are re- 
suspended in complete RPMI 1640 medium in a 50 ml centrifuge tube. Cells are counted 
and volume of matrigel/PBS is calculated.   
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11. Cells are centrifuged at 4C 100 g for 5 min and re-suspended in cold DPBS in a 15 ml 
centrifuge tube.  
12. Cells are centrifuged again at 4C 100 g for 5 min. After removal of DPBS, cells are 
mixed with matrigel and DPBS on ice to a final concentration of 5 million cells per 40 µl 
injection. Ideally matrigel should be half the volume in this step, which is 20 µl of 
matrigel in 40 µl total injection for each mouse. However, the volume of matrigel to be 
added depends on the volume of the cells. There are usually two possible scenarios when 
adding matrigel: 
Scenario 1 (less likely):  cell volume is less than 20 µl. For example if the cell volume is 
15 µl, 20 µl matrigel and 5 µl DPBS are added to make a total volume of 40 µl.  
Scenario 2 (more likely): cell volume is more than 20 µl. For example, if cell volume is 
30 µl, 10 µl matrigel is added to make a total volume of 40 µl. In this case, no DPBS is 
added.   
13. Cells are aliquoted into 1.5 ml microcentrifuge tubes with enough cells to treat 5 mice in 
one tube. Although only 200 µl is needed for 5 mice (or 40 µl per injection), a larger total 
volume of 240 µl to 250 µl is added into each 1.5 ml microcentrifuge tube to compensate 
for customary cell loss during handling and injection. Cells are provided to the Animal 
Studies Core on ice for tumor implantation.  
Example:  For a planned 40 mouse experiment: the theoretical number of cell culture = 
200 million + 40 million extra in 8 tubes = 240 million cells. Therefore, it is 
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recommended to plan for 400 million cells to ensure that there are enough cells for 
handling and injection.  
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